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Establishing statistical methods for quantifying the effects of interventions to pre-
vent infectious diseases is the overall objective of this research. The principal stratifi-
cation framework is frequently implemented to make causal comparisons where naive
methods fail. For HIV vaccine trials, estimates of the causal effect of vaccine on viral
load or post-infection survival is challenging using standard methods because all indi-
viduals do not become infected during the trial. In this scenario, the “principal” effect,
which is the causal effect within a principal stratum, is the effect of vaccine on viral load
for subjects who would be infected during the trial regardless of treatment assignment.
Without strong assumptions, the principal effect is not identifiable and usually requires
bounding, or sensitivity analysis, of the principal effect often resulting in bounds that
are often large and uninformative. Methods for estimating, i.e., bounding, the principal
effect of treatment on competing risks outcomes have not been developed. Furthermore,
situations where bounds on the principal effect can be improved by using baseline co-
variates have not been investigated. The principal stratification framework can also be
used to determine surrogates of vaccine protection, i.e., biomarkers measured during a
trial that are correlated with the desired outcome (infection). Repeated low-dose chal-
lenge studies are often used to evaluate potential vaccines. While these studies more
accurately mimic exposure, the assessment of the potential surrogates greatly depends
on the study design. Evaluation and comparison of different study designs have not
iii
been performed. Therefore, we propose to 1) develop methods to analyze the principal
effect of treatment on competing risks outcomes, 2) investigate the improvement of the
bounds on the principal effect based on baseline covariates, and 3) evaluate designs of
repeated low-dose challenge experiments to assess surrogates of vaccine protection.
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Recent research indicates that at least 40% of HIV infections in infants where infec-
tion time is known can be attributed to mother-to-child transmission (MTCT) through
breastfeeding (Bulterys, Ellington, and Kourtis 2010). In resource limited areas such
as sub-Saharan Africa, options in place of breastfeeding, such as replacement feeding,
which have made HIV MTCT through breast milk uncommon in developed countries
are not viable.
The risk of other diseases such as diarrhea and lower respiratory infections associ-
ated with poor water supplies in these settings make formula use unattractive (Bulterys
et al. 2004). Also, the added cost of animal milk prevents mothers from utilizing that
approach to reducing MTCT in resource-limited settings (Mofenson 2009). As such,
an important area of research in the prevention of MTCT is identifying effective pro-
phylactic treatment(s) for use on the mother (infant) prior to (during) during breast-
feeding. Examples include the KiBS study which assessed the efficacy of a maternal
triple-antiretroviral regimen given to women daily beginning at 34-36 weeks gestation
and until 6 months post-partum, the ZEB study which assessed the efficacy of early
weaning, the SWEN study which assessed the efficacy of prophylactic therapy given
to infants during breastfeeding and the BAN study which assessed the efficacy of pro-
phylactic therapy given to women or infants during breastfeeding (KiBS Study 2011;
Kuhn, et al. 2008; SWEN Study Team 2008; Chasela et al. 2010).
A significant problem with MTCT trial analysis involves early HIV infections. For
each of the trials above, randomization occurred at birth or shortly before. Since MTCT
of HIV can occur anytime before, at, or after birth (De Cock et al. 2000), an infant who
tests positive for HIV early in the trial does not have a clear method of transmission.
Most MTCT trials are interested in only HIV transmission through breast milk. Thus,
if randomization occurs at time 0, a time point τ0 > 0 is often chosen prior to the
beginning of the trial and only randomized infants alive and uninfected at τ0 are con-
sidered for analysis. The removal of these infants from the analysis, while eliminating
the potential bias due to other modes of HIV infection, creates that potential for se-
lection bias, since a mechanism other than randomization determined who was included.
A second issue in the analysis of the risk of HIV infection in MTCT trials is the
presence of competing risks (Alioum et al. 2001), in particular infant death and cessa-
tion of breastfeeding prior to HIV infection. Often infants experiencing HIV-free death
are treated as right censored in the primary analysis, e.g., when computing the Kaplan-
Meier estimator of the cumulative probability of HIV infection (for instance, see Figure
2a of Kumwenda et al. 2008). Unfortunately, interpretation of such estimates is not
straight-forward (Pepe and Mori 1993; Lawless 2003) and a preferred approach is to
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estimate the cumulative incidence of HIV treating death as a competing risk. Simi-
larly, cessation of breastfeeding is also a competing risk of HIV infection because once
an infant is weaned, the likelihood of HIV infection from the mother is essentially zero.
Vaccine Development in Macaques
The use of animal models in pre-clinical vaccine trials can reduce the risk, time and
cost of later clinical trials involving human subjects by providing precursory evidence of
potential risks and efficacy of a candidate vaccine (Girard et al. 2011; Shedlock, Silvestri
and Weiner 2009; Koff 2005). While chimpanzees are the only non-human primate that
can be infected with HIV-1, research on chimps is unfeasible due to ethical and finan-
cial constraints due to expense and endangerment of the species (Shedlock et al. 2009;
Smith 2002; Nath, Schumann, and Boyer 2000). Thus, the majority of pre-clinical stud-
ies of HIV-1 vaccines have used macaques and viral surrogates of HIV, such as simian
immunodeficiency viruses (SIVs), as disease progression of SIVs in macaques parallels
that of HIV in humans (Girard et al. 2011; Shedlock et al. 2009). Virus challenges in
these pre-clinical trials have previously been administered via a single high-dose intra-
venous or mucosal inoculation which frequently resulted in near certain infection of all
animals (Hudgens et al. 2009).
The appeal of single high-dose challenge studies is that high infection rates create
greater chance of observing vaccine efficacy, however this type of trial does not mimic
real exposure. Individuals are more likely to have repeated exposure to low doses of
the disease in non-trial settings implying the high-dose challenge studies are overesti-
mating infections probabilities. For example, the high infection in high-dose challenge
studies do not parallel the low probability of HIV transmission per heterosexual sex
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act, estimated to < 0.01 in various studies of different populations (Gray et al. 2001;
Boily et al. 2009). It is doubtful that vaccines are equally efficacious against high-dose
and low-dose challenges, i.e., the vaccine may create enough protection to prevent lower
doses from causing infections while a high dose could overwhelm the host immune re-
sponse. This implies that potential vaccines that would be efficacious against low-dose
challenges may be rejected due to poor effectiveness in the high-dose challenge studies
(Kim et al. 2006).
1.2 Causal Inference
1.2.1 Introduction
Determining the cause(s) of an outcome is the aim of most public health studies,
both observational and experimental. We wish to say with certainty that event A causes
event B, or that the absence of event A causes the absence of event B, e.g., vaccination
prevents disease. This idea of causation implies a certain “causal pathway” where we
can identify which event(s) cause the other (Rothman 1976). Most researchers desire
to perform and analyze these studies with simple or conventional methods. In many
cases, causation cannot be assessed from either type of research using conventional
methods due to mitigating circumstances. In observational studies, a lack of temporal-
ity or unmeasurable variables often hinder the ability to determine causation without
sophisticated methods or strong assumptions (Rubin 1974). While most randomized
studies are designed to answer, and are able to answer, causal questions using simple
approaches, situations can arise that would prevent these naive methods from deter-
mining causation, i.e., the BAN study. When these conventional methods fail, methods
and frameworks are developed to determine causation. The general term for this type
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of research is causal inference.
One quantity of interest in causal inference is the causal effect (CE) or the effect of an
intervention on some outcome of interest. For example, the causal effect of angiotensin-
converting enzyme (ACE) inhibitor use on the prevention of a second heart attack is
the ability of the ACE inhibitor to prolong the time to a second heart attack. This can
be quantified as a difference of survival times (e.g. average time to second heart attack
while using an ACE inhibitor minus the average time to second heart attack when not
using an ACE inhibitor). In infection prevention studies, the causal effect of vaccine is
measured by vaccine efficacy (VE), defined as the reduction of disease incidence within
vaccinated individuals versus disease incidence in unvaccinated individuals (Halloran,
Longini, Struchiner 1999). Inference about these effects can be made using a number
of modeling techniques including four major types for health-sciences research: graph-
ical models (causal diagrams), potential outcome models, sufficient component cause
models, and structural equations models (Greenland and Brumback 2002).
Using the potential outcomes or counterfactual approach, suppose n individuals are
observed or selected and each individual is randomly assigned one of two treatments.
Without loss of generality, assume that there are two possible treatments and let Zi = 0
if subject i is assigned treatment 0 (control) and Zi = 1 if assigned treatment 1 (active
treatment). A necessary condition for estimating causal effects is that the possibility
for each individual to receive any of the treatments exists. This condition allows in-
dividuals to have specific outcomes had they been assigned a specific treatment, i.e.,
individuals have potential outcomes respective to each treatment. If we let Yi(Zi) be
some outcome for individual i when assigned treatment Zi, the potential outcomes
under our scenario are Yi(0) and Yi(1). These potential outcomes are assumed to be
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fixed and observable if assigned the respective treatment. This allows us to manipulate
which potential outcome is observed by changing the treatment assigned since there
is “no causation without manipulation”(Holland 1986). The major drawback to this
approach is that we can only observe one of the potential outcomes, since an individual
can only be assigned one treatment. The other potential outcome is termed as a coun-
terfactual, since it is the outcome that is contrary to fact. Thus, we define the observed
outcome as Y obsi = ZiYi(1) + (1 − Zi)Yi(0) (Cole and Frangakis 2009). A standard
assumption states that the treatment assignment of individual i does not affect the
potential outcomes of other individuals (i.e., there is no interference) and there are not
multiple forms of treatment, i.e., the stable unit treatment value assumption (SUTVA)
holds (Rubin 1980).
1.2.2 Principal Stratification
The principal stratification framework was developed by Frangakis and Rubin (2002)
to provide causal interpretations where standard procedures would not allow. De-
veloped using the potential outcomes approach (Rubin 1974, Neyman et al. 1990),
principal strata are defined by the potential outcomes of a variable measured post-
randomization or post-treatment. Two goals of principal stratification are to reduce
post-treatment selection bias created by making causal comparisons of outcomes that
do not have a common set of units or individuals and identify principal surrogates.
In most trials of infectious disease prevention the post-randomization variable of
interest is infection status at some predetermined time τ0 with the outcome measured
in only those infected (viral loads) or uninfected (time to infection) at τ0. In these
cases, the principal strata are defined by the potential infection status at τ0 under all
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possible treatment assignments. Let Si(Zi) be individual i’s potential infection status
at τ0 when given treatment Zi. In the simple case of only one treatment group and one
control group, there are four principal strata; always infected (AI) (Si(0) = Si(1) = 1),
protected (Si(0) = 1, Si(1) = 0), never infected (NI) (Si(0) = Si(1) = 0), and harmed
(Si(0) = 0, Si(1) = 0). For example, a person who is assigned Zi = 0 and becomes
infected at τ0 (Si = 1), they are either in the AI or the protected strata.
The principal effect is the causal comparison of treatment within the principal strata
of interest. When the principal strata are non-empty, principal effects are not identifi-
able from the data without strong assumptions. The monotonicity assumption states
that the treatment does no harm to patients or more formally
Si(0) ≥ Si(1), ∀i. (1.1)
Under monotonicity and SUTVA, one half of the causal effect of interest can be identi-
fied from the data, since there is not a harmed principal strata. While the role principal
stratification in research has caused recent debate (Pearl 2011; Gilbert, Hudgens, and
Wolfson 2011), principal stratification can be used to identify causal effects under sce-
narios where they are otherwise impossible.
For example, in HIV vaccine trials where viral load post-infection is of importance,
the AI principal strata is of interest. Here the causal comparison would be the differ-
ence in average viral load when taking control versus treatment among individuals who
would have been infected regardless of treatment assignment. A fundamental problem
with this approach involves principal strata membership. Since only one of the two
potential outcomes Si(0) and Si(1) is observed, an individuals principal strata mem-
bership is unidentifiable from the data without possibly strong assumptions.
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1.2.3 Sensitivity Analysis and Bounds Within Principal Strata
Assuming monotonicity in an HIV vaccine trial, all vaccinated individuals are in the
AI strata. On the other hand, individuals assigned control who become infected are a
mixture of individuals from the AI and protected principal strata. Thus the distribution
of potential outcomes when assigned control in the AI strata is not identifiable from the
observed data. However, the proportion of infected controls who are in the AI strata
is identifiable. Let V E = Pr[Si(1) = 0|Si(0) = 1] implying that 1 − V E = Pr[Si(1) =
1|Si(0) = 1]. Then, 1 − V E is the proportion we seek. We can think of 1 − V E
as a measure of potential selection bias (Hudgens, Hoering, and Self 2003 (HHS)).
HHS developed a framework where stochastic lower and upper bounds of this causal
effect can be estimated corresponding to extreme selection bias models. Specifically,
let FC(y) be the cumulative distribution function (CDF) of viral load among infected
control participants such that the causal effect of interest is CE = FAIT (y) − FAIC (y).
Then,
FC(y) = (1− V E)FAIC (y) + (V E)F protectedC (y), (1.2)
where FAIC (y) (F
protected
C (y)) is the CDF of viral load for infected vaccinees in the
AI(protected) principal strata. Under monotonicity, FAIV (y) = FV (y) and is thus iden-
tifiable from the observed data. For what HHS calls the extreme lower selection bias




1− V E , 0
}
.








They then present simulation results demonstrating the performance of hypothesis tests
using these bounds. Since 1−V E is only a measure of potential selection bias, the true
bias is likely not as extreme as the bounds presented in HHS.
Building upon HHS, Gilbert, Bosch, and Hudgens (2003)(GBH) developed sensi-
tivity analysis for a continuous outcome based on the mixing equation (1.2). With Zi,
Si(Zi), Yi(Zi), and the principal strata defined as before, they assumed a sensitivity pa-
rameter, β, that allowed for selection bias models between the extreme cases presented
in HHS. Recalculating (1.2), using the probability density function, yields
fAIC (y) = W
−1w(y)fC(y),
where w(y) = Pr[Si(1) = 1|Yi(0) = y, Si(0) = 1] and W =
∫∞
−∞w(x)fC(x)dx = 1−V E.
Assuming a logistic relationship between β and 1 − V E gives w(y) = w(y|α, β) =
exp (α + βy)/(1 + exp (α + βy)). This results in
FAIC (y|β) = (1− V E)−1
∫ y
−∞
exp (α + βx)
1 + exp (α + βx)
dFC(x), (1.3)
where for a fixed β, α is the solution to the equation FC(y|β) = 1. Similar to HHS,
GBH created test statistics and hypothesis tests based on the selection models with
critical values computed using the “controls only” approach. Simulations were con-
ducted under different selection bias models with varying values of β. They showed
that when presuming the correct value of β, their tests had correct Type I error and
decent power, independent of the value of V E assumed. However, an incorrectly spec-
ified β yielded poor performance. Their suggestion was to perform sensitivity analysis
across a continuously indexed range of βs. Gains in power or precision may be achieved
by restricting the range of β based on prior information elicited from subject matter
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experts (Scharfstein et al. 2006; Shepherd, Gilbert, Mehrotra 2007). Hudgens and Hal-
loran (2006) extended this work to a binary outcome.
A method for sensitivity analysis within principal strata with a time-to-event out-
come was developed by Shepherd, Gilbert, and Lumley (2007)(SGL). Consider the
same setup as GBH but instead of a continuous potential outcome Yi(Zi) we have a
time-to-event outcome Ti(Zi). Allowing for potential censoring times, the observed
outcome for an individual who become infected is the pair Y obsi = min(Ti, Ci) and
∆i = I(Yi = Ti), where I() is the usual indicator function. Let Fz(t) be the CDF of
failure times for subjects randomized to the group z = 0, 1. The causal effect of inter-
est is SCE(t) = FAI0 (t) − FAI1 (t), the survival causal effect in the AI stratum at time
t. Assuming the same mixing equation (1.2), SGL proposed nonparametric extreme
selection models equivalent to HHS and GBH with similar upper and lower bounds.










1− V E , 1
}
,
which mimic those in HHS. Following GBH, they assume a semiparametric selection
bias model with logistic weighting that allow for bias models between the nonparamet-
ric extreme models. In fact, SGL’s selection bias model is found by replacing FC(y),
the CDF of the continuous outcome Yi for the control group, in (1.3) with F0(t). It
requires an additional set of assumptions to estimate SGL’s model in practice, since
1 − V E = ∫∞
0
w(x)dF0(x)dx requires knowledge of F0(t) after time τ1, the end of the
trial follow-up period, and a solution for α for a fixed β. For simplicity, they assume
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that the logistic weights are constant after τ1, which makes α identifiable from the data.
For both types of models, SGL present analytic variance estimates for each estimator of
the causal effect. SGL also present the setup for a parametric model but focus on per-
formance of the non- and semiparametric models. Their simulations show both types
of model have minimal bias when the correct β is specified. For most cases, confidence
intervals based on their estimators have proper coverage independent of the choice of β.
1.2.4 Covariates and Principal Stratification
Frangakis and Rubin (2002) formed the principal stratification framework assuming
that the analysis was performed within cells defined by baseline covariates. Shepherd
et al. (2006) developed sensitivity analysis of the causal effect conditional on baseline
covariates in a fully parametric setting. Jemiai et al. (2007) expanded the methods of
Shepherd et al. (2006) allowing for semiparametric estimation. There are other exam-
ples of principal stratification within levels of baseline covariates, e.g., Sjo¨lander et al.
(2009).
Grilli and Mealli (2008) presented nonparametric unadjusted bounds on the causal
effect, CE, within principal strata under a number of different assumptions. They sug-
gest that these unadjusted bounds for CE can be improved by creating bounds within
cells defined by a baseline covariate and then recovering then adjusting the bounds
through a weighted average. Let X be a baseline covariate and CEx be the causal
effect conditional on X = x such that CE =
∑









CElx Pr[X = x]
and CEuX =
∑
CEux Pr[X = x]. Grilli and Mealli (2008) performed this method on
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data from an employment study with mixed results. For some choices of X the ad-
justed bounds of CE had improvement on only one side of the unadjusted bounds,
i.e., CElX > CE
l and CEuX > CE
u so improvement was seen on only one side of the
bounds. Other choices of X actually worsened the bounds. The reason for only partial
improvement was not addressed.
Using baseline covariates to model the probability of being in a certain principal
strata or “principal score” was first established in Hill, Waldfogel, and Brooks-Gunn
(2002). The process outlined within was more fully developed by Jo and Stuart (2009).
Their idea was to model the probability that an individual was a ‘complier’ using base-
line covariates. In the compliance literature the basic principal strata are defined by
a patients treatment assignment (Zi) and actual use of treatment (Si(Zi)). Compliers
are subjects who would take the treatment when assigned treatment and would not
take the treatment when assigned control, i.e., Si(0) = 0, Si(1) = 1. Jo and Stuart
assume that no patient assigned control has access to treatment which removes the
possibility of two principal strata, defiers (Si(0) = 1, Si(1) = 0) and always-takers
(Si(0) = Si(1) = 1). That implies that all patients are either compliers or never-takers
(Si(0) = Si(1) = 0). Thus, the principal score is the probability that an individual
is a complier. An analogous ‘compliance score’ was created previously by Follmann
(2000), which while mathematically equivalent, was created before, therefore outside,
the principal stratification framework. In both Jo and Stuart (2009) and Follmann
(2000), a two-step model is performed by first estimating the principal scores using lo-
gistic regression then using a parametric model for the outcome estimated by matching
or weighting by the principal scores.
A similar notion exists within the ‘truncation by death’ literature. Zhang, Rubin,
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and Mealli (2009) developed likelihood based methods that estimated the principal
scores and the outcome model simultaneously. Using HIV vaccine trial notation, let
Gi represent the principal strata membership for subject i, i.e., Gi = (Si(0), Si(1)). In
general, piSi(0)Si(1) = Pr[Gi = g], e.g., pi11 is the probability that a subject is in the AI
strata. Their model allows for these probabilities to vary by subject.
1.2.5 Principal Surrogates
In HIV vaccine trials, participants cannot be followed forever, implying the primary
clinical outcome of HIV infection cannot be measured in all participants, preventing an
accurate measurement of VE. A surrogate endpoint that is predictive of the primary
outcome that can be measured for all subjects within the trial would be useful.
While not the first to use the term, Prentice (1989) laid the foundation for the
current surrogate literature. Let Zi be treatment assignment Zi = 0, 1. Let Si(Zi)
be a binary post-randomization variable and assume monotonicity, i.e., Si(0) ≥ Si(1)
for all i. Additionally, let Yi(Zi) be the outcome of interest. For Prentice, for Si
to be a surrogate endpoint for the true outcome Yi under treatment Zi, Yi would be
independent of Zi conditional on Si. Frangakis and Rubin (2002) term this a ‘statistical’
surrogate and demonstrate how a statistical surrogate can exist while not having a
causal relationship to the outcome. They state that a variable is a ‘principal’ surrogate
if all comparisons of the outcome within all strata where Si(0) = Si(1) results in
equality, i.e., there is no effect of treatment on the outcome given Si(0) = Si(1) = s
for all s. Let Si = 1 indicate if a person has a high potential surrogate value ,Si = 0
otherwise, and let f(x) be some measurement of interest, i.e. risk of infection. Si
would be a principal surrogate if f(Yi(0)|Si(0) = Si(1) = s)− f(Yi(1)|Si(0) = Si(1) =
s) = 0 for s = 0, 1. However, since principal strata membership is unknown, only
f(Yi(z)|Si(z) = s), z = 0, 1 can be identified from the data, which allows a variable to
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meet Prentice’s criteria (a statistical surrogate) but would not be a principal surrogate.
Likewise, a variable can be a principal surrogate but not a statistical surrogate. Using
Example 1 in Table 1.1, Si is a principal surrogate but is not a statistical surrogate
since the treatment effect is 0 in the strata where Si(0) = Si(1) but the treatment
effect is nonzero when Si = 0 in the observed data. Example 2 illustrates the reverse
situation.
Since Frangakis and Rubin (2002) defined principal surrogacy, researchers have de-
veloped further criteria, especially in the vaccine literature. A vaccine-induced immune
response (surrogate endpoint) that is predictive of infection, a correlate of protection,
is the ‘holy grail’ of vaccine trials (Halloran, Longini, and Struchiner 2009). Qin et
al. (2007) defined three different levels of confidence in a biomarker to be a correlate
of protection. The first level indicates a measurement that predicts the primary end-
point in a particular population and is called a correlate of risk. The higher levels are
called surrogates of protection (SoP) and have two levels of generalizability. A SoP is
a correlate of risk that predicts a vaccines efficacy based on comparisons between the
vaccinated and unvaccinated subjects immunological measurements. The level 1 SoP,
or specific SoP (Sadoff and Wittes 2007), can predict VE in the same setting in which
it was identified (same vaccine, population, etc). The level 2 SoP can predict VE in a
variety of settings and is termed a general SoP or a bridging SoP (Pearl and Barenboim
2011). While a general SoP is desirable, a specific SoP is still of scientific use (Gilbert,
Hudgens, and Wolfson 2011).
Joffe and Greene (2009) summarized four competing frameworks that have been
used for evaluating potential surrogate endpoints. The first two frameworks considered
are under the causal-effects paradigm, where the effect of treatment on the surrogate
and the effect of the surrogate on the clinical outcome are used to predict the effect of
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treatment on the clinical outcome. The first, developed by Prentice (1989), defines a
surrogate S as a valid surrogate when a hypothesis test of no relationship between S
and treatment is also a valid test of no relationship between treatment and the clini-
cal outcome. He proposed three criteria where when all criteria are met the previous
holds and S is a ‘true surrogate’. The second framework involves modeling the direct
and indirect effects of the surrogate on the clinical outcome. In general, both causal-
effects paradigm frameworks require direct manipulation of S to determine the causal
effects, which makes determination of proxy surrogates, a measurable related variable
to an unmeasurable S, possible. The second set of two frameworks are under a causal-
association paradigm, where the effect of treatment on the surrogate is associated with
the effect of treatment on the outcome. The first design in the causal-association
paradigm uses meta-analysis to examine the effect of a randomized treatment on the
clinical outcome across a number of studies. The second is principal surrogacy as de-
scribed previously.
Gilbert and Hudgens (2008) developed a principal stratification estimand they call
the “causal effect predictiveness (CEP ) surface” to measure a biomarkers accuracy
as a specific surrogate, or surrogate value. Built upon Frangakis and Rubin (2002),
and Follmann (2006), CEP is conditional on not yet having the primary outcome
under either treatment assignment at time τ , the time that the biomarker is collected.
Formally, CEP is defined as
CEP (s1, s0) = P (Y (0) = 1|S(1) = s1, S(0) = s0)− P (Y (1) = 1|S(1) = s1, S(0) = s0)
= E(Y (0)− Y (1)|S(1) = s1, S(0) = s0)
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(or some different contrast), where Y (Z) (S(Z)) is primary binary outcome (poten-
tial biomarker) if assigned treatment Z, Z = 0 is control and Z = 1 is treatment
(Gilbert, Hudgens, and Wolfson 2011). They argue that one can use CEP (s1, s0) to
determine the association between S(1)−S(0) and Y (1)−Y (0), the goal of predicting
VE, since previous estimands only measured the association between S(1) and Y (1)
(Gilbert and Hudgens 2008; Gilbert, Hudgens, and Wolfson 2011). Gilbert and Hudgens
(2008) also consider summary functions of the associative and dissociative effects of a
biomarker, namely the expected associative effect (EAE) and the expected dissociative
effect (EDE). They also define the proportion associative (PA) effect by
PAEw = |EAEw|/|EDE|+ |EAEw|, (1.4)
with the convention that |0|/(|0| + |0|) = 0.5. PAEw is the relative proportion of pri-
mary outcome effects for those with and without surrogate effects. Hudgens and Gilbert
(2009) assessed the vaccine effects in repeated-low-dose experiments. They suggest that
PAE, PAEw from (1.4) with w(., .) = 1, can be used as a summary measure of the
surrogate value of S. Using the framework for Follmann (2006), they define the transi-
tion probability from uninfected to infected as a probit model which allows PAE to be
estimated easily. Huang and Gilbert (2011) developed a method to evaluate the joint
surrogacy of multiple biomarkers.
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Table 1.1: Examples demonstrate possible scenarios where a biomarker is a statistical
surrogate but not a principal surrogate and vice versa.
Average potential Average potential Observed
post-treatment variable outcome Si, Yi Si, Yi
Si(0) Si(1) Yi(0) Yi(1) Zi = 0 Zi = 1
Example 1: Si a principal surrogate but not a statistical surrogate
0 0 10 10
0, 15
0, 10
0 1 20 40
1, 40
1 1 40 40 1, 40
Example 2: Si a not principal surrogate but is a statistical surrogate
0 0 15 20
0, 20
0, 20
0 1 25 25
1, 40
1 1 40 55 1, 40
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Chapter 2
Competing Risks Outcomes Within
Principal Strata
2.1 Introduction
Every year approximately 200,000 infants become infected with HIV through breast-
feeding; in the absence of treatment, half of these infants will die within two years of
birth (WHO 2007; UN AIDS 2007). In clinical trials to prevent MTCT of HIV through
breast milk, investigators are often interested in comparing interventions conditional
on the infant being alive and uninfected up to a certain time point during the trial
(van der Horst et al. 2009; Chasela et al. 2010; Kilewo et al. 2009; Kumwenda et al.
2008). Specifically, when randomization occurs at birth (time 0), a time point τ0 > 0
is often chosen prior to the beginning of the trial and only randomized infants alive
and uninfected at τ0 are considered for analysis. For example, in the Breastfeeding,
Antiretroviral, and Nutrition (BAN) study (van der Horst et al. 2009; Chasela et al.
2010) infants were randomized at birth but the primary analysis included only infants
HIV uninfected and alive at τ0 = 2 weeks. Infants infected prior to 2 weeks were ex-
cluded because these transmissions likely occurred in utero or during labor and delivery,
whereas the primary objective of the trial was to assess the effects of interventions to
prevent infection due to breast milk. Similar exclusions were made in the primary
analysis of the SWEN and PEPI trials (Bedri et al. 2008; Kumwenda et al. 2008).
There are two aspects of the analysis described above that are the focus of this paper.
First, an analysis comparing risk of HIV infection between trial arms among infants
who are alive and uninfected at time τ0 after randomization is subject to selection
bias. One method to protect against selection bias in this scenario entails principal
stratification (Frangakis and Rubin 2002). Principal stratification uses the potential
outcomes of a variable collected post-randomization to define strata of individuals.
In the MTCT trial setting, the principal stratum of interest is infants who would be
alive and uninfected by time τ0 under either treatment assignment. Because principal
stratum membership is not affected by treatment assignment, comparisons between
trial arms within a particular principal stratum are not subject to selection bias. For a
recent discussion of the strengths and weaknesses of principal stratification, see Pearl
(2011) and subsequent responses such as VanderWeele (2011).
The second aspect in the analysis of the effect of treatment on the risk of HIV in-
fection in MTCT trials is the presence of competing risks (Alioum 2001). In particular,
death or weaning prior to HIV transmission are competing risks for HIV infection since
these events (death, weaning) can preclude HIV infection from occurring. Likewise,
HIV infection precludes the possibility of an HIV-free death or weaning prior to HIV
infection. One analytical approach that avoids the complication of competing risks is to
use a composite endpoint, such as time until HIV infection or death. Using a composite
endpoint simplifies analysis and has the advantage of providing a single measure of the
overall effect of treatment. However, such an analysis does not provide inference about
whether the treatment is having an effect on the risk of HIV infection, death, or both
endpoints. Another common approach in the analysis of MTCT trials is to treat infants
experiencing HIV-free death as right censored, e.g., when computing the Kaplan-Meier
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estimator of the cumulative probability of HIV infection (for instance, see Figure 2a of
Kumwenda et al. 2008). It is well known that computing the Kaplan-Meier estimator
by right censoring competing events does not in general yield a consistent estimator of
the cumulative risk of the event of interest (Tsiatis 1998; Andersen, Abildstrom, and
Rosthøj 2002); in the MTCT setting such Kaplan-Meier estimators will tend to overes-
timate the risk of HIV infection when there is a non-zero probability of death prior to
HIV infection. A third approach, adopted in this paper, is to estimate the cumulative
incidence functions of each competing event, namely HIV, death, and weaning. The
resulting estimates have a straightforward interpretation as the cumulative risk of each
event in settings such as the trial where the other events may occur. Contrasts is the
estimated risks between trial arms can then be used to assess treatment effects on each
of the competing events. While Bekaert, Vansteelandt, and Martens (2010) investigate
the effect of time-varying covariates in the presence of competing risks, they assume
that there is a potential event time for each competing risk which we will avoid.
Previous work on estimating treatment effects within principal strata has considered
binary outcomes (e.g., Hudgens and Halloran 2006), continuous outcomes (e.g., Gilbert
et al. 2003) and survival outcomes (e.g., Hayden et al. (2005) and Shepherd et al.
(2007)). In this paper we develop methods for estimating treatment effects within
principal strata for a survival outcome in the presence of competing risks. In the absence
of competing risks the developed methods essentially reduce to those of Shepherd et al.
(2007). The outline of the remainder of this chapter is as follows. In Section 2 notation
and assumptions are discussed. In Section 3 inferential methods for the causal effect
of interest are presented. The finite sample performance of the methods are assessed
in a simulation study in Section 4. These simulations also illustrate how misleading
inferences can arise if selection bias are ignored. In Section 5 the methods are applied
to investigate the effect of infant antiretroviral therapy (ART) on the cumulative risk
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of HIV infection in the BAN trial. A brief discussion is given in Section 6.
2.2 Notation and Assumptions
Suppose n individuals are randomly assigned one of two treatments, 0 or 1, at
baseline (birth or time 0). For i = 1, . . . , n, let Zi = 0 if subject i is assigned treatment
0 and Zi = 1 otherwise. Let n0 =
∑
(1−Zi) and n1 =
∑
Zi, where here and throughout∑
=
∑n
i=1. Without loss of generality, assume Zi = 0 corresponds to placebo or control,
and Zi = 1 corresponds to active treatment. In the BAN study analysis, Zi = 1 will
refer to the infant ART arm and Zi = 0 will refer to the control arm. Suppose the
primary objective is to assess the effect of treatment on the time Ti (from baseline) until
some particular event occurs. Assume there are k possible causes or types of events and
let Ji denote the event type for individual i with Ji ∈ {1, . . . , k}. In the BAN study
there are k = 3 competing risks: HIV infection (Ji = 1), death prior to HIV infection
or weaning (Ji = 2), or cessation of breastfeeding prior to HIV infection (Ji = 3).
Suppose in the analysis of the effect of treatment Zi on (Ti, Ji) we would like to
condition on some binary post-randomization variable Si (taking on values 0 or 1)
measured at some pre-specified post-randomization time τ0 > 0. For instance, in the
analysis of BAN it is desired to assess the effect of treatment in infants alive and
uninfected at time τ0; in this case we let Si = 1 if an infant becomes infected or dies
by τ0 and Si = 0 otherwise. Note for the BAN example that Si = I(Ti ≤ τ0, Ji ≤ 2)
where I(·) is the usual indicator function, however in the methods developed below Si
need not be defined in terms of Ti or Ji.
Define Ci to be a potential right censoring time and assume τ0 ≤ Ci, i.e., no indi-
viduals drop out of the study prior to τ0 such that Si is always observed. Let τ1 denote
the maximum length of follow-up for the study such that any individual who has not
had an event or dropped out of the study by time τ1 is administratively censored at
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that time, i.e., Ci ≤ τ1. Let Yi = min{Ti, Ci} and ∆i = I(Yi = Ti). Due to censoring,
instead of (Ti, Ci, Ji) we only observe (Yi, Ji∆i); i.e., Ti and Ji are observed if and only
if individual i is not right censored.
Let Ti(z) be the potential survival time when assigned treatment z for z = 0, 1 such
that Ti = (1− Zi)Ti(0) + ZiTi(1). Define Ci(z), Si(z), and Ji(z) similarly. Assume the
treatment assignment of individual i does not affect the potential outcomes of other
individuals (i.e., there is no interference) and there are not multiple forms of treatment,
i.e., the stable unit treatment value assumption (SUTVA) holds (Rubin 1980). Let
Wi = (Si(0), Si(1), Ti(0), Ti(1), Ji(0), Ji(1), Ci(0), Ci(1)) denote the vector of potential
outcomes and Oi = (Zi, Si, Yi, Ji∆i) denote the vector of observable random variables.
Assume individuals in the study are a random sample from a larger population such
that W1, . . . ,Wn and O1, . . . , On are iid copies of W and O respectively.
Principal strata can be defined by sets of individuals with the same potential out-
come pair (Si(0) = s0, Si(1) = s1). Define the never infected (NI) principal stratum to
be individuals with Si(0) = Si(1) = 0, i.e., individuals who would be alive and unin-
fected at τ0 regardless of treatment assignment. Similarly define the harmed stratum
as those individuals with Si(0) = 0, Si(1) = 1; the protected stratum as those indi-
viduals with Si(0) = 1, Si(1) = 0; and the doomed stratum as those individuals with
Si(0) = Si(1) = 1. Motivated by MTCT studies of HIV, we focus on drawing inference
about causal effects in the NI principal stratum. For example, in the BAN study we
are interested in the principal stratum of infants who would be alive and not infected
with HIV by τ0 = 2 weeks under either randomization assignment.
In the presence of competing risks, a quantity of interest is the cumulative incidence
function (CIF) or subdistribution function of (T, J). Let F (t, j) = P (T ≤ t, J = j)
denote the CIF, i.e., the probability of having event j at or before time t. Define the
causal estimand of interest to be CE(t, j) = FNI1 (t, j)− FNI0 (t, j) for t ∈ [τ0, τ1] where
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FNIz (t, j) = Pr[Ti(z) ≤ t, Ji(z) = j|Si(0) = Si(1) = 0] for z = 0, 1. In words, CE(t, j)
is the difference in the probability of having an event of type j by time t for treatment
0 compared to treatment 1 within the NI principal stratum. For example, in the BAN
study (where j = 1 corresponds to HIV infection), CE(28, 1) is the difference in the
probability of HIV infection by 28 weeks between the two study arms among infants
who would be alive and HIV negative by τ0 weeks regardless of treatment assignment.
In the analysis of BAN, CE(28, 1) was of particular interest because per protocol a
primary endpoint of the trial was HIV infection by 28 weeks (van der Horst et al.
2009).
To draw inference about CE(t, j) we make the following assumptions:
Assumption 2.1 Independent treatment assignment: Zi ⊥ Wi
Assumption 2.2 Monotonicity: Si(1) ≤ Si(0) for all i
Assumption 2.3 Independent censoring: Ci(z) ⊥ {Ti(z), Ji(z), Si(z)} for z = 0, 1
Assumption 2.1 is plausible in randomized clinical trials. Assumption 2.2 is a strong
assumption that must be considered carefully and is discussed further in Section 2.5
in the context of the BAN study. Methods not requiring the monotonicity assumption
are discussed in Section 6. Assumption 2.3 is a common assumption when analyzing
competing risks data. In the infant ART and control arms of BAN, 15% of participants
were administratively censored at τ1 = 28 weeks and 12% were censored at earlier time
points due to drop-out from the study prior to week 28.
Under Assumptions 2.1 and 2.2, Zi = 0 and Si = 0 imply Si(0) = Si(1) = 0; i.e.,
individuals who are alive and uninfected by τ0 when assigned control must be members
of the NI principal stratum. Letting F0(t, j) = Pr[Ti(0) ≤ t, Ji(0) = j|Si(0) = 0], it
follows under Assumptions 2.1 – 2.2 that FNI0 (t, j) = F0(t, j), which is identifiable from
the observable data under Assumption 2.3. However FNI1 (t, j) remains unidentifiable
under Assumptions 2.1 – 2.3 because individuals who are alive and uninfected by τ0
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when assigned treatment (Zi = 1) are a mixture of individuals from the NI and pro-
tected principal strata. In particular, following Gilbert et al. (2003)nocitegilbert2003b,
one can show
F1(t, j) = γF
NI
1 (t, j) + (1− γ)F prot1 (t, j), (2.1)
where γ = Pr[Si(0) = 0|Si(1) = 0] is the probability an individual is uninfected under
control given they would be uninfected under treatment, F1(t, j) = Pr[Ti(1) ≤ t, Ji(1) =
j|Si(1) = 0] and F prot1 (t, j) = Pr[Ti(1) ≤ t, Ji(1) = j|Si(0) = 1, Si(1) = 0].
To proceed, one can introduce an additional assumption about the selective effect
of conditioning on Si which renders F
NI
1 (t, j) identifiable. For example, following Hud-
gens and Halloran (2006), large-sample upper and lower bounds can be obtained by
considering extreme selection bias models. The upper bound selection model is given
by assuming either F prot1 (t, j) = 0 or F
NI
1 (t, j) = 1, while the lower bound selection
model is given by assuming either F prot1 (t, j) = 1 or F
NI
1 (t, j) = 0. By (2.1), these
models are equivalent to assuming either






FNI1 (t, j) = max
{





Estimating CE(t, j) under (2.2) or (2.3) is useful in bounding the estimate of the causal
effect above and beyond any possible selective effects induced by conditioning on Si = 0.
The true degree of selection bias may be considerably less than that assumed by (2.2)
or (2.3). Therefore, we consider a class of selection models that includes the extreme
models above as special cases. Through sensitivity analysis over the entire class (as
in Robins et al. 2000 and Gilbert et al. 2003), the relationship between the assumed
degree of selection bias and inference about CE(t, j) can be explored. These selection
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models are semiparametric in the sense that no additional restrictions are placed on
the distribution of the observable random variables O1, . . . , On but an unidentifiable




FNI1 (t, j)/{1− FNI1 (t, j)}
F prot1 (t, j)/{1− F prot1 (t, j)}
. (2.4)
The parameter βj equals the log odds ratio of having an event of type j by time t
under treatment assignment z = 1 in the NI principal stratum versus the protected
principal stratum. Note Assumption 2.4 allows for the log odds to differ across event
types as indicated by the subscript on β. Also note (2.4) is unverifiable since βj is
not identifiable from the observable data. For fixed βj, under Assumptions 2.1 – 2.4
FNI1 (t, j; βj) is identifiable from the observable data and CE(t, j) can be estimated as
described in Section 2.3 below. The extreme models (2.2) and (2.3) can be viewed as
special cases of Assumption 2.4 as βj →∞ and βj → −∞. We refer to βj = 0 as the no
selection bias model because in this case the odds of having an event of type j by time t
are the same in the NI and protected principal strata. Sensitivity analysis of inference
about CE(t, j) can be conducted by letting βj range from −∞ to ∞. Gains in power
or precision may be achieved by restricting the range of βj based on prior information
about βj elicited from subject matter experts (Scharfstein et al. 2006; Shepherd et al.
2007).
2.3 Inference
In this section we first consider nonparametric estimation of CE(t, j) under the
extreme selection models (2.2) and (2.3). Then inference for CE(t, j) under the semi-
parametric selection model (2.4) given some value of βj is discussed in Section 2.3.2.
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The construction of uncertainty intervals about CE(t, j) is considered in Section 2.3.3.
2.3.1 Nonparametric Estimation: Bounds
Under Assumptions 2.1 - 2.3 consistent estimators of FNI1 (t, j) assuming (2.2) or
(2.3) are given, respectively, by




and FˆNI,low1 (t, j) = max
{










(1− Si)Zi/n1 , 1
}
,
and Fˆ1(t, j) is the Aalen-Johansen estimator (Aalen and Johansen 1978) of F1(t, j)
calculated using (Yi, Ji∆i) for individuals with Zi = 1 and Si = 0. It can be shown
that γˆ and Fˆ1(t, j) are nonparametric maximum likelihood estimators (NPMLEs) of
γ and F1(t, j). Thus the estimators in (2.5) can be viewed as NPMLEs of F
NI
1 (t, j).
Because Assumptions 2.1 and 2.2 imply FNI0 (t, j) = F0(t, j), consistent estimators
of CE(t, j) assuming either (2.2) or (2.3) are ĈE
up
(t, j) = FˆNI,up1 (t, j) − Fˆ0(t, j) or
ĈE
low
(t, j) = FˆNI,low1 (t, j)− Fˆ0(t, j), where Fˆ0(t, j) is the Aalen-Johansen estimator of
F0(t, j) calculated using (Yi, Ji∆i) for individuals with Zi = Si = 0. In the nomencla-




(t, j)] is an estimated
ignorance region of CE(t, j).
If 0 < γ < 1, then γˆ is asymptotically normal. The Aalen-Johansen estimators
Fˆz(t, j), for z = 0, 1 are asymptotically normal assuming 0 < Fz(t, j) < 1 and certain
regularity conditions (Aalen, Borgan, and Gjessing 2008). Therefore, FˆNI,up1 (t, j) is
asymptotically normal if, in addition to these conditions,
F1(t, j) < γ. (2.6)
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If (2.6) does not hold, then FˆNI,up1 (t, j)
p−→ 1 and hence is not asymptotically normal.
Under conditions where FˆNI,up1 (t, j) is asymptotically normal, a consistent estimator of
the variance of FˆNI,up1 (t, j) is



















where v̂ar{Fˆ1(t, j)} is a consistent estimator of the variance of Fˆ1(t, j) (e.g., see Aalen
et al. 2008, Section 3.4.5) and Nz =
∑
I(Si = 0, Zi = z). Similarly Fˆ
NI,low
1 (t, j) is
asymptotically normal if, in addition to the conditions above,
1− γ < F1(t, j). (2.8)
If (2.8) does not hold, FˆNI,low1 (t, j)
p−→ 0 and hence is not asymptotically normal. If
FˆNI,low1 (t, j) is asymptotically normal, the variance can be consistently estimated by



















Derivations of (2.7) and (2.9) are given in the appendix. When (2.6) and (2.8) hold,
pointwise Wald-type confidence intervals for CE(t, j) can be constructed in the usual
manner. Alternatively, the bootstrap percentile method can be used for computing
confidence intervals of CE(t, j). If (2.6) and (2.8) do not hold, then FˆNI,up1 (t, j)
p−→ 1
and FˆNI,low1 (t, j)
p−→ 0, i.e., the bounds are non-informative. Note that conditions (2.6)
and (2.8) can be assessed based on observed data by comparing γˆ and Fˆ1(t, j).
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2.3.2 Semiparametric Estimation
Under Assumptions 2.1 – 2.4, for fixed βj a semiparametric estimator of F
NI
1 (t, j)
can be constructed by plugging Fˆ1(t, j) and γˆ into equation (2.1) and then simulta-
neously solving (2.1) and (2.4) for FNI1 (t, j). This can be accomplished by expressing
F prot1 (t, j) as a function of βj and F
NI
1 (t, j) using (2.4), replacing F
prot
1 (t, j) by this ex-
pression in (2.1), and finding the solution to (2.1) using a one-dimensional line search.
Define the solution as FˆNI1 (t, j; βj) and let the corresponding estimator of the causal
effect be ĈE(t, j; βj) = Fˆ
NI
1 (t, j; βj)− Fˆ0(t, j). Without a closed form for FˆNI1 (t, j; βj),
confidence intervals of FNI1 (t, j) and CE(t, j) for an assumed value of βj can be con-
structed using the bootstrap percentile method; alternatively, Wald-type confidence
intervals can be constructed based on bootstrap estimates of var{FˆNI1 (t, j; βj)} and
var{ĈE(t, j; βj)}.
Note limβj→∞ ĈE(t, j; βj) = ĈE
up
(t, j) and limβj→−∞ ĈE(t, j; βj) = ĈE
low
(t, j),
i.e., the estimators that arise from the extreme selection models (2.2) and (2.3) are
special cases of the estimators from the semiparametric bias model (2.4). Under the
no selection model βj = 0, ĈE(t, j; βj) = Fˆ1(t, j) − Fˆ0(t, j), i.e., the causal effect
is estimated by the difference in Aalen-Johansen estimators from the two treatment
groups as in a standard competing risks analysis. In other words, assuming the no
selection model gives rise to a naive or “net” estimator (Frangakis and Rubin 2002)
which simply compares subsets of the two randomization groups conditional on being
observed HIV free and alive at τ0.
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2.3.3 Uncertainty Regions
The pointwise confidence intervals described in Sections 2.3.1 and 2.3.2 will contain
CE(t, j) with the stated coverage probability provided the correct value of βj is as-
sumed. However, the true value of βj is not identifiable from the observed data. There-
fore, following Vansteelandt et al. (2006), it is useful to also construct a (1 − α)100%
uncertainty interval which contains CE(t, j) with probability 1− α without condition-
ing on any assumption about the value of βj. Under the assumptions given in Section
2.3.1 where ĈE
up
(t, j) and ĈE
low
(t, j) are consistent and asymptotically normal, a





(t, j)}1/2, ĈEup(t, j) + c∗α/2v̂ar{ĈE
up
(t, j)}1/2]
where c∗α/2 can be computed using equation (4.3) of Vansteelandt et al. (2006),
v̂ar{ĈElow(t, j)} = v̂ar{FˆNI,low1 (t, j)}+ v̂ar{Fˆ0(t, j)} and v̂ar{ĈE
up
(t, j)} =
v̂ar{FˆNI,up1 (t, j)}+ v̂ar{Fˆ0(t, j)}.
2.4 Simulation Study
Simulations were conducted to evaluate the performance of the methods described
in Section 2.3 for drawing inference about CE(t, j). Data were simulated based on
the BAN study under five models: βj = −∞,−1, 0, 1,∞ for fixed j. These five
choices of βj correspond to the two extreme selection models (βj = −∞,∞), two
intermediate selection models (βj = −1, 1), and the no selection bias model (βj = 0).
The Gompertz distribution was used to simulate competing risks data (Jeong and
Fine 2006). Under the Gompertz distribution the CIF can be expressed as F (t, j) =
1− exp [λj{1− exp (αjt)}/αj] where {α1, . . . , αk, λ1, . . . , λk} are chosen such that
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∑k
j=1 Pr[J = j] =
∑k
j=1 F (∞, j) = 1. For the simulation study k = 3 and the param-
eters {α1, α2, α3, λ1, λ2, λ3} were selected such that F1(28, 1) = 0.02, F1(28, 2) = 0.02,
F1(28, 3) = 0.70, and
∑3
j=1 F1(∞, j) = 1. These probabilities correspond roughly to
the estimated risk of HIV infection (j = 1), death (j = 2) prior to HIV infection or
weaning, and cessation of breastfeeding prior to HIV infection (j = 3) at 28 weeks
in the BAN study among infants randomized to the infant ART arm who were HIV
negative and alive at 2 weeks.
Simulations were conducted under two scenarios (for each of the five models). For
the first scenario we let γ = 0.9884, corresponding to the estimated value of γ from
the BAN study. In this scenario we considered estimating CE(28, 1), i.e., the effect of
treatment on risk HIV infection at 28 weeks. Note (2.6) and (2.8) hold in this scenario
for t = 28 and j = 1 such that the estimators of the bounds are asymptotically normal.
Because γ = 0.9884 is near the boundary value of 1, for the second scenario we let
γ = 0.75. In order for (2.6) and (2.8) to hold in the second scenario, we considered
estimating CE(28, 3), i.e., the effect of treatment on weaning at 28 weeks. For the
first scenario simulations were conducted under the alternative hypothesis CE(28, 1) =
−0.05, i.e., the risk of HIV infection is lowered by 5% due to treatment. For the second
scenario simulations were conducted where CE(28, 3) = 0.05, i.e., women are more
likely to breastfeed at 28 weeks when the infant receives ART. For each model and
each scenario, data sets of n = 1520 iid copies of W were simulated according to the
following steps. The description below is for the first scenario where j = 1 is the event
of interest; simulations were conducted analogously for the second scenario where j = 3
is the event of interest.
Step 1. Si(1) was drawn from a Bernoulli(0.0458), where 0.0458 was the estimated
risk of infection or death at two weeks in the infant ART arm of BAN.
Step 2. If Si(1) = 1, then by monotonicity Si(0) = 1. In this case we let Ti(0) =
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Ji(0) = Ti(1) = Ji(1) = ∗ because the survival time and failure type for
individuals with Si = 1 are not used by any of the estimators of CE(t, j).
Step 3. If Si(1) = 0, then (Ti(1), Ji(1)) were generated according to the Gompertz
models described above. In particular, first Ji(1) was generated from a multi-
nomial distribution with cell probabilities 1− exp(λj/αj) for j = 1, 2, 3. Then
Ti(1) was set equal to τ0 + Ui where Ui was randomly generated from the
conditional distribution Pr[Ti(1) ≤ t|Ji(1) = j] = F (t, j)/Pr[Ji(1) = j] us-
ing the inverse probability transformation. Generating Ti(1) in this fashion
guarantees that Ti(1) > τ0 = 2 whenever Si(1) = 0.
Step 4. If Si(1) = 0, Si(0) was generated as follows. For β1 = −∞, Si(0) = I(Ti(1) <
q
(1−γ)
1 , Ji(1) = 1) where q
(1−γ)
j is defined in general such that Pr[Ti(1) ≤
q
(1−γ)
j , Ji(1) = j|Si(1) = 0] = 1− γ. Note for the first scenario (2.8) holds for
t = 28 and j = 1, guaranteeing the existence of q
(1−γ)
1 . For, β1 = −1, 0, 1,
the value of F prot1 (28, 1; β1) was found by solving (2.1) and (2.4) simulta-
neously, and then Si(0) ∼ Bernoulli(pβ1) where pβ1 = (1 − γ)I(Ti(1) <
28, Ji(1) = 1)F
prot
1 (28, 1; β1)/F1(28, 1) + (1 − γ){1 − I(Ti(1) < 28, Ji(1) =
1)}{1− F prot1 (28, 1; β1)}/{1− F1(28, 1)}. For β1 =∞, Si(0) ∼ Bernoulli(p∞)
where p∞ = (1−γ){1−I(Ti(1) < 28, Ji(1) = 1)}/{1−F1(28, 1)}. Note for the
first scenario (2.6) holds for t = 28 and j = 1, implying 1− γ < 1− F1(28, 1)
thus ensuring p∞ < 1.
Step 5. If Si(0) = 0, then we let Ji(0) = Ji(1). If Si(0) = 0 and Ji(0) = 1, then
Ti(0) = Ti(1)/, where  was chosen such that CE(28, 1) = −0.05. If Si(0) = 0
and Ji(0) 6= 1, then Ti(0) = Ti(1). If Si(0) = 1, then we set Ti(0) = Ji(0) = ∗.
Step 6. Ci(0) and Ci(1) were generated from exponential distributions with means 29
weeks and 18 weeks respectively.
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Step 7. Zi was randomly assigned such that n1 = 852 and n0 = 668.
Step 8. Given Zi, we set Yi = min{Ti(Zi), Ci(Zi)}, ∆i = I(Yi = Ti(Zi)), Ji = Ji(Zi),
and Si = Si(Zi).
These steps resulted in simulated data sets satisfying Assumptions 2.1 – 2.4 with
CE(28, 1) = −0.05 for the first scenario. For each data set simulated, ĈE(28, 1; βj)
was computed for βj = −∞,−1, 0, 1,∞. Bootstrap percentile and Wald 95% confi-
dence intervals as well as the uncertainty intervals described in Section 2.3.3 were also
computed for each simulated data set, assumed value of β1, and estimator of CE(28, 1).
Table 2.1 reports the mean relative bias of ĈE(28, j; βj) based on 10,000 simulated
data sets for both scenarios (γ = 0.9884, j = 1, and γ = 0.75, j = 3) and each model
(βj = −∞,−1, 0, 1,∞). The proposed estimator ĈE(28, j; βj) is approximately unbi-
ased when βj is correctly specified; for incorrectly specified βj the relative bias can be
quite large. For example, if β1 is (incorrectly) assumed to be zero, corresponding to
the naive analysis that simply compares infants HIV free and alive at two weeks from
each study arm, when in fact β1 = −∞, then the relative bias of ĈE(28, 1; β1) is 23%.
This demonstrates how a naive analysis that ignores the potential for selection bias can
yield incorrect inference. This is demonstrated further in the scenario where γ = 0.75,
in which case misspecifying β3 leads to even greater relative bias.
Table 2.2 shows the empirical coverage probabilities of 95% pointwise bootstrap
confidence intervals based on 500 bootstrap replications per simulated data set. When
the correct βj is specified, the confidence intervals associated with ĈE(28, j; βj) have
approximately 95% coverage. Similar results were found using Wald confidence intervals
(results not shown). Because βj is not identifiable from the observable data, coverage of
the uncertainty regions is perhaps of more practical interest. For the 50,000 simulated
data sets from the first scenario (i.e., combining across the 10,000 data sets for each of
the five values of βj), the empirical coverage of the 95% pointwise uncertainty regions
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was 97%. Similarly for the second scenario, the empirical coverage of the uncertainty
intervals was 97%.
2.5 Application to BAN Study
The BAN study was a randomized clinical trial to assess interventions for the pre-
vention of breast milk transmission of HIV in 2369 HIV infected mothers and their
infants in Lilongwe, Malawi (van der Horst et al. 2009; Chasela et al. 2010). There
were three arms in the BAN study: daily ART for the infant, daily ART for the
mother, or control. While the primary analysis of the study considered comparisons
of both ART arms to control, we will focus on comparing the infant ART and control
arms only. In March 2008 the data and safety monitoring board stopped the control
arm due to efficacy but recommended continued enrollment of mother/infant pairs into
the two active treatment arms. This led to an imbalance in the final number of infants
randomized to the three arms, with 852 infants in the infant ART arm and 668 infants
in the control arm. In the infant ART arm there were 37 HIV infections and 2 deaths
before τ0 = 2 weeks, while the control arm had 36 HIV infections and 2 infant deaths
prior to 2 weeks. Thus γˆ = (630/668)/(813/852) = 0.9884, as in the first scenario of
the simulations in Section 2.4. Among infants HIV free and alive at 2 weeks, in the
infant ART (control) arm 12 (32) became HIV infected, 588 (384) weaned prior to HIV
infection, and 5 (6) died prior to HIV infection or weaning by 28 weeks. Figure 2.1
shows the Aalen-Johansen estimates of the cumulative risk of HIV, death prior to HIV
infection or weaning, and cessation of breastfeeding prior to HIV infection for infants
who were alive and uninfected at 2 weeks as in a standard analysis, i.e., assuming the
no selection model βj = 0 holds for all j. Figure 1(a) suggests a difference in the risk
of HIV infection between the infant ART arm and the control arm, however direct
comparison between the arms is subject to selection bias.
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Figure 2.2 shows the semiparametric sensitivity analysis described in Section 2.3.2.
The plot depicts ĈE(28, 1; β1) and pointwise 95% Wald confidence intervals for each
value of β1 (using bootstrap variance estimates). Note for the infant ART arm Fˆ1(28, 1) =
0.0141, suggesting (2.6) and (2.8) hold for t = 28 and j = 1. The estimated ignorance
region for CE(28, 1) equals [-0.056, -0.044] and the estimated 95% uncertainty interval
equals [-0.078, -0.025]. This estimated uncertainty interval was computed using boot-
strap variance estimates; using the analytical variance estimates (2.7) and (2.9) yielded
a slightly wider uncertainty interval of [-0.084, -0.025]. In either case, because the un-
certainty interval excludes 0, we conclude there is evidence of a causal effect of infant
ART on the cumulative incidence of HIV at 28 weeks in the NI stratum. Moreover,
without any assumptions about the selection bias mechanism, we are 95% confident
daily infant ART lowers the risk of HIV infection at 28 weeks between 3% and 8%.
The veracity of these results relies on several key assumptions. While interference
between infants was not likely, SUTVA could have been violated by changes in the
infant ART regimen. Per protocol, if an infant on ART had an adverse event due to
the study drug (nevirapine), the ART was changed (to lamivudine) and the infant re-
mained in the study. Thus not all infants were on the same treatment for the duration
of the study. Therefore, the effect of ART being estimated can be viewed as an average
causal effect over all administered ARTs (Vanderweele 2011). While this interpreta-
tion answers the hypothesis proposed for the BAN study, it does not indicate which
particular ART causes the greatest reduction in risk of HIV infection. Assumption 2.1
seems reasonable because treatment was randomized. While mothers were not blinded,
they were counseled to breastfeed their infants regardless of randomization assignment
and self-reported frequency of exclusive breastfeeding was comparable between study
arms (Chasela et al. 2010). The BAN study principal investigator, Dr. Charles van der
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Horst, indicated that monotonicity (Assumption 2.2) is reasonable (personal commu-
nication). Dr. van der Horst conjectured that an infant could have an adverse reaction
to ART leading to increased susceptibility to HIV infection but he felt this was “highly
unlikely.” Monotonicity is also supported by the estimated risk of HIV infection or
death at two weeks being lower in the infant ART arm than in the control arm.
Finally, note that two of the three endpoints in BAN were interval censored. In
particular, the HIV infection times of the infants were interval censored, known only to
be between the last negative and first positive HIV tests. Similarly, the actual timing
of weaning is known only to be visits where the mother reported still breastfeeding and
weaning. On the other hand, the time of death was known exactly for all infants. Other
analyses of the BAN data have found that formally accounting for interval censoring
almost always gives nearly the same result as using the midpoint or right endpoint of
the interval. This is not surprising given the visits in the BAN study were fairly close
together, typically two to four weeks apart. In settings where the intervals are wider,
midpoint or right endpoint imputation may yield misleading results. Instead, a non-
parametric estimator of F1(t, j) that allows for interval censored event times (Hudgens,
Satten, and Longini 2001) can be employed in place of the Aalen-Johansen estimator.
Inference that formally accounts for interval censoring is challenging however, owing
to slow rates of convergence and non-standard limiting distributions of non-parametric
estimators (for continuous time models; Groeneboom, Maathuis, and Wellner 2008a,b).
2.6 Discussion
The objective of many MTCT trials is to determine differences in the cumulative
risk of breastfeeding transmission of HIV between study arms conditional on infants
being HIV free and alive by some time point τ0 > 0. Here we have presented methods
for evaluating the effect of treatment on the cumulative risk of HIV within a principal
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stratum when death and weaning are competing risks. Large sample non-parametric
bounds and a semi-parametric sensitivity analysis model were developed, and the meth-
ods were applied to the BAN study, a large, recent MTCT trial. A simulation study
was presented demonstrating that the proposed methods perform well in finite samples
similar to the BAN study. The simulations also illustrated how analyses that ignore
the potential for selection bias by simply conditioning on being HIV free and alive at
τ0 can give misleading results in settings similar to the BAN study.
The analysis of the BAN study indicates infant ART reduces the risk of HIV infec-
tion by 28 weeks in infants who would be HIV free and alive at two weeks regardless
of treatment assignment. The proposed methods could be applied in other settings
as well. For example, BAN investigators (personal communication) were interested in
comparing the risk of HIV infection or death by 48 weeks conditional on infants being
HIV free and alive at 28 weeks; here τ0 = 28 weeks is further from time 0 and the
potential for selection bias is even greater than the analysis presented in Section 2.5.
Another example is given by the Zambia Exclusive Breastfeeding (ZEB) study, a ran-
domized MTCT study conducted to evaluate whether abrupt weaning at four months
compared with continued breastfeeding increases survival of children of HIV-infected
mothers (Kuhn et al. 2008). Randomization occurred at one month postpartum in
the ZEB study, however Kuhn et al. (2008) presented a comparison of the randomized
groups conditional on infants being HIV free and breastfeeding at four months.
A key assumption of the methods described in this paper is monotonicity, which
implies that the treatment is no worse than control for any individual in terms of the
intermediate variable S. This assumption seems reasonable in the analysis of the BAN
study presented in Section 5, but in other settings it may be unrealistic. For example,
monotonicity might be considered dubious in an analysis comparing the two active arms
of the BAN trial, i.e., maternal ART versus infant ART. In such settings methods that
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relax or do not require this assumption would be needed. Following Zhang and Rubin
(2003), nonparametric bounds analogous to those in Section 2 can be derived without
assuming monotonicity. Specifically, note that F0(t, j) = φF
NI
0 (t, j)+(1−φ)F harm0 (t, j),
where φ = Pr[Si(1) = 0|Si(0) = 0] and F harm0 (t, j) = Pr[Ti(0) ≤ t, Ji(0) = j|Si(0) =
0, Si(1) = 1]. If γ and φ were identifiable, then bounds for F
NI
0 (t, j) can be constructed
analogous to (2.2) and (2.3) and combined with bounds for FNI1 (t, j) to obtain the
following bounds on CE(t, j):
CElow(t, j) = max
{

























However, without the monotonicity assumption γ and φ are not identifiable. Let pi =
Pr[Si(0) = 0, Si(1) = 1] and note that
γ = Pr[Si(0) = 0|Si(1) = 0] = Pr[Si(0) = 0, Si(1) = 0]
Pr[Si(1) = 0]
=
Pr[Si(0) = 0]− pi
Pr[Si(1) = 0]
and
φ = Pr[Si(1) = 0|Si(0) = 0] = Pr[Si(0) = 0, Si(1) = 0]
Pr[Si(0) = 0]
=
Pr[Si(0) = 0]− pi
Pr[Si(0) = 0]
are identifiable from the observed data for a fixed value of pi. Thus, the lower bound of
CE(t, j) is found by minimizing (2.10) over pi where max{0,Pr[Si(0) = 0]−Pr[Si(1) =
0]} ≤ pi ≤ min{Pr[Si(0) = 0],Pr[Si(1) = 1]}. Likewise, the upper bound of CE(t, j)
is found by maximizing (2.11) over the same range of pi. Sensitivity analysis could be
performed by adapting the methods of Shepherd, Gilbert, and Dupont (2011). For





FNI0 (t, j)/{1− FNI0 (t, j)}
F harm0 (t, j)/{1− F harm0 (t, j)}
. (2.12)
Sensitivity analysis under Assumptions 2.1, 2.3, 2.4, and 2.5 would be performed
by varying pi over max{0,Pr[Si(0) = 0] − Pr[Si(1) = 0]} ≤ pi ≤ min{Pr[Si(0) =
0],Pr[Si(1) = 1]} and ηj, βj each over (−∞,∞). The resulting inference will be more
precise if the ranges of pi, ηj, and βj can be further restricted based on prior information
elicited from subject matter experts.
For the MTCT research motivating this work, interest focused on the principal
stratum of infants HIV free and alive at τ0 under either treatment assignment. The
methods developed could also be applied to infants HIV infected and alive at τ0 un-
der either treatment where T might denote the time until death from various causes.
Beyond MTCT trials, the methods developed could be applied in other settings where
inference about treatment effects within principal strata is of interest (e.g., truncation-
by-death or non-compliance) and the endpoint is a time-to-event outcome subject to
competing risks. Further research might entail allowing the cumulative incidence func-
tions to depend on baseline covariates (e.g., as in Jeong and Fine (2007)).
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Figure 2.1: Estimated cumulative incidence functions, Fˆz(23, j), for the three events
from the BAN study: (a) HIV infection, (b) HIV-free death prior to weaning, and (c)
cessation of breastfeeding prior to HIV infection. For each panel, Zi = 0 (control) is
represented by the solid line (—) and Zi = 1 (infant ART) is represented by the dashed
line (−−−).
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Figure 2.2: Sensitivity analysis of the effect of infant ART on the cumulative incidence
of HIV at 28 weeks for the BAN study. The solid line — denotes ĈE(28, 1; β1) and
the dotted lines · · · denote pointwise 95% confidence intervals. The estimated non-
parametric bounds corresponding to β1 = −∞ and β1 =∞ are given by ◦.
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Table 2.1: Empirical relative bias of estimates of CE(28, j) from simulation study
described in Section 2.4 for both scenarios. Bold entries correspond to estimates where
the assumed βj was correct. Relative bias of ĈE(28, j; βj) defined as {ĈE(28, j; βj)−
CE(28, j)}/CE(28, j).
True parameters Assumed βj
γ CE βj −∞ −1 0 1 ∞
0.9884 -0.05 −∞ 0.02 0.22 0.23 0.24 0.24
-1 -0.19 0.01 0.01 0.02 0.02
0 -0.21 -0.01 0.00 0.00 0.01
1 -0.20 -0.01 0.00 0.00 0.00
∞ -0.21 -0.01 -0.00 0.00 0.00
0.75 0.05 −∞ -0.01 -1.10 -2.01 -3.13 -6.69
-1 1.02 -0.01 -0.88 -1.96 -5.32
0 2.00 0.91 -0.01 -1.12 -4.67
1 2.66 1.77 0.98 0.00 -2.93
∞ 6.50 5.44 4.55 3.45 0.00
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Table 2.2: Empirical coverage of pointwise 95% bootstrap percentile confidence intervals
of CE(28, j) from simulation study described in Section 2.4 for both scenarios. Bold
entries correspond to estimates where the assumed βj was correct.
True parameters Assumed βj
γ CE βj −∞ −1 0 1 ∞
0.9884 -0.05 −∞ 0.95 0.81 0.80 0.80 0.79
-1 0.90 0.95 0.94 0.94 0.94
0 0.88 0.94 0.94 0.94 0.94
1 0.89 0.95 0.95 0.95 0.95
∞ 0.89 0.95 0.95 0.95 0.95
0.75 0.05 −∞ 0.95 0.55 0.06 0.00 0.00
-1 0.66 0.94 0.65 0.06 0.00
0 0.14 0.66 0.94 0.47 0.00
1 0.01 0.12 0.55 0.94 0.01
∞ 0.00 0.00 0.00 0.00 0.94
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Chapter 3
Sharpening Bounds on Principal
Effects with Covariates
3.1 Introduction
Often in randomized trials to evaluate the effect of a treatment, inference is ham-
pered by possible selection bias induced by conditioning on or adjusting for a variable
measured post-randomization. One approach that avoids potential selection bias is
to focus inference on the causal effect within a principal strata of interest, i.e., the
principal effect (Frangakis and Rubin 2002). Principal strata are defined by the pair
of potential outcomes under either treatment assignment of the post-randomization
variable. In vaccine trials, a principal stratum of interest may be individuals who
would be infected at a certain time regardless of vaccine status (Shepherd et al. 2011).
In studies of interventions to prevent mother-to-child transmission (MTCT) of HIV
through breastfeeding, a principal stratum of interest is infants who would be unin-
fected at a certain time regardless of treatment (Nolen and Hudgens 2011). In either
case, principal strata membership is unidentifiable from the observable data without
strong assumptions because only one of the two post-randomization variable potential
outcomes is ever observed for an individual. In turn, the principal effect of interest is
not identifiable. One approach to cope with lack of identifiability is to conduct sensi-
tivity analysis wherein some model is assumed indexed by an unidentifiable parameter
conditional on which the principal effect is identifiable. Inference about the principal
effect is conducted conditional on some value of the unidentifiable parameter and then
sensitivity of the inference is examined by considering different values of the parame-
ter. An alternative approach entails drawing inference about bounds on the principal
effects, e.g., Zhang and Rubin (2003). Informally, these extreme bounds provide the
smallest and largest possible values of the principal effect consistent with the observed
data. This approach is appealing in that typically bounds can be obtained under mini-
mal assumptions. However, in many cases the bounds may be quite wide and therefore
not particularly informative about the principal effect.
Grilli and Mealli (2008) derived nonparametric bounds on the principal effect under
a number of different assumptions. They suggested these bounds can be improved
(or narrowed) by creating bounds within strata defined by a baseline covariate and
combining these stratum specific bounds by taking a weighted average to obtain new
adjusted bounds on the principal effect. Grilli and Mealli (2008) performed this method
on data from an employment study with mixed results. The adjusted bounds were an
improvement on only one side of the unadjusted bounds, i.e., the adjusted lower bound
was larger than the unadjusted lower bound but the adjusted upper bound was also
larger than the unadjusted upper bound. The reason for only partial improvement
was not addressed and characterization of which circumstances will lead to improved
bounds was not investigated.
In this work we consider sharpening (or narrowing) the large sample bounds of a
principal effect using information from a baseline categorical covariate, as proposed
by Grilli and Mealli (2008). In Section 3.2, notation and assumptions are introduced.
Section 3.3 addresses non-identifiability of the principal effect and in Section 3.4 the
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unadjusted bounds are reviewed. In Section 3.5, adjusted bounds are presented by
taking a weighted average of bounds within levels of the baseline covariate. Section
3.6 contains the main result, giving necessary and sufficient conditions under which
the covariate adjusted bounds improve upon (i.e., are narrower than) the unadjusted
bounds. Cases in which adjusting for the covariate will identify the principal effect
are illustrated in Section 3.8. In Section 3.7, the adjusted and unadjusted bounds are
considered using data from a recent, large MTCT study. A brief discussion is presented
in Section 3.9. Proofs of the propositions in Section 3.6 are given in the Appendix.
3.2 Notation and Assumptions
To motivate, throughout we consider the MTCT example where infants of HIV
positive mothers are randomized at birth to treatment or control. Suppose n infants
are enrolled in a MTCT study and randomly assigned one of two treatments, 0 or 1, at
baseline (birth or time 0). For i = 1, . . . , n, let Zi = 0 if infant i is assigned treatment
0 and Zi = 1 otherwise. Without loss of generality, assume Zi = 0 corresponds to
control, and Zi = 1 corresponds to active treatment. Let Xi be some binary variable
measured at baseline (prior to randomization) taking on values 0 or 1. Let Si denote
whether infant i is infected at a pre-specified post-randomization time point τ0 > 0,
i.e., Si = 1 if the infant is infected at τ0, Si = 0 otherwise. Let Yi be a binary outcome
measured only in infants with Si = 0. Let Si(z) denoted the potential value of Si when
assigned treatment z for z = 0, 1 such that Si = (1 − Zi)Si(0) + ZiSi(1). Define Yi(z)
similarly. We assume the ith infant’s treatment assignment does not affect the potential
outcomes of other infants (i.e., no interference) and that there are not multiple forms
of treatment, i.e., the stable unit treatment value assumption (SUTVA) holds (Rubin
1980).
Principal strata are defined by sets of infants with the same potential outcome
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pair (Si(0) = s0, Si(1) = s1). Define the always infected (AI) principal stratum to be
infants with s0 = s1 = 1, i.e., infants who would be infected at τ0 regardless of treatment
assignment. Similarly define the harmed stratum as those infants with s0 = 0, s1 = 1;
the protected stratum as those infants with s0 = 1, s1 = 0; and the never infected (NI)
stratum as those infants with s0 = s1 = 0.
Here and throughout assume Assumption 1: Zi ⊥ (Xi, Si(0), Si(1), Yi(0), Yi(1))
Assumption 2 (Monotonicity): Si(1) ≤ Si(0) for all i Assumption 1 will hold in ran-
domized trials. Monotonicity assumes that treatment does no harm, i.e., there are no
infants who would be infected only if treated. Under Assumption 2, there are only
three possible principal strata: AI, NI, and protected. In MTCT studies to prevent
breastmilk transmission of HIV, investigators are interested in the NI stratum because
infections prior to τ0 could be due to the birthing process and not breastfeeding. The
causal estimand of interest, the principal effect, is the effect of treatment on Yi in infants
who would be uninfected and alive at τ0 under either treatment assignment, namely
CE = Pr[Yi(1) = 1|Si(0) = Si(1) = 0]− Pr[Yi(0) = 1|Si(0) = Si(1) = 0].
Below we consider large sample bounds for CE that do and do not adjust for baseline
covariates.
3.3 Partial Identifiability
In this section we consider the identifiability of CE. Let θzst = Pr[Yi(z) = 1|Si(1) =
s, Si(0) = t], piz = Pr[Yi(z) = 1|Si(z) = 0], and γ = Pr[Si(0) = 0|Si(1) = 0], such that
CE = θ100−θ000. Assume γ > 0 as otherwise the NI stratum is empty with probability
1. Under Assumptions 1 and 2, θ000 = Pr[Yi = 1|Si = 0, Zi = 0], which is identifiable
from the observed data. However, θ100 is not identifiable. Following Hudgens and
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Halloran (2006) note
Pr[Yi(1) = 1|Si(1) = 0] = Pr[Yi(1) = 1|Si(1) = Si(0) = 0] Pr[Si(0) = 0|Si(1) = 0]
+ Pr[Yi(1) = 1|Si(1) = 0, Si(0) = 1] Pr[Si(0) = 1|Si(1) = 0],
i.e.,
pi1 = γθ100 + (1− γ)θ101. (3.1)






Pr[Si = 0|Z = 0]
Pr[Si = 0|Z = 1] .
On the other hand, θ100 and θ101 are not identifiable because infants who were treated
and uninfected at τ0 are a mixture of infants from the protected and NI strata. Solving







Equation (3.2) describes a line with intercept pi1/γ and slope −(1 − γ)/γ. Any point
on this line will give rise to the same observed data distribution. Two populations will
have the same observable data if all else being equal pi1 ∗ γ + Pr[Yi(1) = 1|Si(0) =
1, Si(1) = 0] ∗ (1− γ) is the same in the two populations.
Note that if γ = 1, pi1 = 1, or pi0 = 0 then CE is identifiable. If γ = 1, then (3.2)
is a horizontal line with intercept pi1 and thus θ100 = pi1. If pi1 = 1, then (3.1) implies
θ100 = 1. Likewise, if pi1 = 0, then (3.1) implies θ100 = 0. Otherwise, if γ < 1 and




In this section, we present large sample bounds that ignore the baseline covariate
X. Large sample bounds for CE are found by first bounding θ100. The upper bound
for θ100 is obtained by assuming θ101 = 0 or θ100 = 1. Likewise, the lower bound for
θ100 is obtained by assuming θ101 = 1 or θ100 = 0. These bounds can be envisaged as
corresponding to the point where the line (3.2) intersects the unit square (Hudgens and
Halloran 2006).







and θl100 = max
{










u = θu100− θ000 and
CEl = θl100 − θ000. These bounds will be referred to as “unadjusted” bounds since no
information from the covariate is used.
To illustrate, let the probabilities corresponding to a fictitious trial of MTCT of
HIV be γ = 0.95, pi1 = 0.02, and pi0 = 0.05. Using (3.3) for this trial, θ
u
100 =
min{0.02/0.95,1} = 0.021 and θl100 = max{(0.02 − (1 − 0.95))/0.95, 0} = 0. This
gives the unadjusted bounds as [CEl, CEu] = [0− 0.05, 0.021− 0.05] = [−0.05,−0.029]
since θ000 = pi0. Let the probabilities for a second fictitious trial be γ = 0.80, pi1 = 0.85,
and pi0 = 0.95. Thus, θ
u
100 = 1 and θ
l
100 = 0.813, implying the unadjusted bounds are
[CEl, CEu] = [−0.137, 0.05]. These two fictitious trials will be revisited in the next
section.
3.5 Adjusted Bounds
Here we consider the method proposed by Grilli and Mealli (2008) for adjusting
the large sample bounds using the binary baseline covariate X, i.e., bounds will be
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obtained within strata defined define by X and then weighted averages of the stratum
specific bounds will be computed. Let θzstx = Pr[Yi(z) = 1|Si(1) = s, Si(0) = t,Xi =
x], γx = Pr[Si(0) = 0|Si(1) = 0, Xi = x], pizx = Pr[Yi(z) = 1|Si(1) = 0, Xi = x],









x=0. As in the unadjusted case, θ100x is not














and θl100x = max
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Under Assumptions 1 and 2, φx is identifiable because Pr[Xi = x|Zi = 0, Si = 0] =
Pr[Xi = x|Si(0) = 0] = Pr[Xi = x|Si(1) = Si(0) = 0]. Therefore, identifiable bounds










This leads to adjusted bounds CEuX = θ
u
100X − θ000 and CElX = θl100X − θ000.
Table 3.1 contains the values of two baseline covariates, X1 and X2, for each of the
fictional trials discussed in Section 3.4. For the first trial and X1, by (3.6), we have
θu1000 = min{0.035/0.995, 1} = 0.035, θl1000 = max{(0.035−(1−0.995))/0.995, 0} = 0.03,
θu1001 = 0.011, and θ
l
1001 = 0. Thus, θ
u
100X = 0.035 ∗ 0.419 + 0.011 ∗ 0.581 = 0.021 and
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θl100X = 0.013. Therefore, there is improvement to the lower bound on the causal
effect when adjusting for X1, from [CE
l, CEu] = [−0.05,−0.029] to [CElX1 , CEuX1 ] =
[−0.037,−0.029]. However, using X2 in the first trial there is no improvement since




100X = 0 = θ
l
100.
For the second trial and X1, θ
u
1000 = 0.854, θ
l
1000 = 0.73, θ
u
1001 = 1, and θ
l
1001 =
0.878. Thus, θu100X = 0.935 and θ
l
100X = 0.813. Here adjusting for X1 yields a
smaller upper bound resulting in narrower bounds, i.e., [CEl, CEu] = [−0.137, 0.05]
to [CElX1 , CE
u
X1
] = [−0.137,−0.015]. In fact, the adjusted upper bound is less than
the null value of 0, indicating treatment has an effect in the NI principal stratum. On
the other hand, using X2 there was again no improvement since θ
u
100X = 1 = θ
u
100 and
θl100X = 0.813 = θ
l
100.
A graphical depiction of the unadjusted and adjusted bounds is given in Figure
3.1. The unadjusted bounds are found where the solid lines intersect the unit square.
Bounds within strata defined by X correspond to where the dashed and dotted lines
intersect the unit square. The adjusted bounds, represented by ◦ and +, are weighted
averages of these stratum specific bounds. For example, in the upper left panel corre-
sponding to trial 1 and X1, we see that θ
l
100X is larger than θ
l
100 since the + is above 0,
the point where the solid line intersects the horizontal axis.
3.6 Improvement of the Bounds
The examples in the preceding section illustrate that adjusting for a baseline co-
variate may or may not improve the bounds on CE. In this section, we give necessary
and sufficient conditions for when the adjusted bounds (3.7) will be narrower than the
unadjusted bounds of (3.3). Proofs for all propositions are given in the Appendix.
Proposition 1. [θl100X , θ
u
100X ] ⊆ [θl100, θu100] for any baseline binary covariate X.
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According to Proposition 1, the adjusted bounds will be at least as narrow as the
unadjusted bounds no matter the choice of X. To characterize the conditions under
which the adjusted bounds are strictly narrower than the unadjusted bounds, assume
Xi takes on values x and x
′ and consider the following two criteria:
pi1x < γx and pi1x′ > γx′ , (3.8)
and
pi1x > (1− γx) and pi1x′ < (1− γx′), (3.9)
where the value of x in (3.8) and (3.9) is not necessarily the same. In words, (3.8)
and (3.9) indicate that Xi is informative about relation of the distribution of Si(0)
given Si(1) = 0 and the distribution of Yi(1) given Si(1) = 0. On the other hand,
if Xi is uninformative about this relation then neither (3.8) nor (3.9) will hold. For
example, if Xi is independent of Si(0) given Si(1) = 0 and if Xi is independent of
Yi(1) given Si(1) = 0, then neither (3.8) nor (3.9) will hold. Using (3.8) and (3.9), the
following propositions characterize exactly the situations when the adjusted bounds
will be narrower.
Proposition 2. θu100X < θ
u
100 if and only if X satisfies (3.8).
Proposition 2 states (3.8) is a necessary and sufficient condition for the adjusted
upper bound for θ100 to be smaller than the unadjusted bound. This proposition is
exemplified in the second fictional trial from Section 3.5 using X1, where pi10 < γ0 and
pi11 > γ1.
Proposition 3. θl100X > θ
l
100 if and only if X satisfies (3.9).
Proposition 3 provides the necessary and sufficient condition for the adjusted lower
bound to be θ100 larger than the unadjusted bound. This proposition is illustrated in
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the first fictional trial from Section 3.5 using X1, where pi10 > (1−γ0) and pi11 < (1−γ1).
It follows immediately from Propositions 2 and 3 that if (3.8) and (3.9) both hold
then the adjusted bounds are strictly contained within the unadjusted bounds and if
neither hold, the adjusted and unadjusted bounds are equal.
3.7 Illustration
Grilli and Mealli (2008) analyzed data on academic careers and job opportunities
of university students and found that the estimated adjusted bounds were not strictly
contained within the estimated unadjusted bounds, apparently contradicting Proposi-
tion 1. In this section we consider a MTCT trial where a similar relationship between
the estimated adjusted and unadjusted bounds is found.
The Breastfeeding, Antiretoviral, and Nutrition (BAN) study was a randomized
clinical trial to assess interventions for the prevention of breast milk transmission of
HIV in 2369 HIV infected mothers and their infants in Lilongwe, Malawi (Chasela et
al. 2010). There were three arms in the BAN study: daily antiretroviral therapy (ART)
for the infant, daily ART for the mother, or control. While the primary analysis of the
study considered comparisons of both ART arms to control, we will focus on comparing
the infant ART and control arms only. Per protocol, infants who died or were infected
in the first 2 weeks post-treatment were excluded from the primary analysis, creating
the potential for selection bias. Let Si = 1 if the infant became HIV positive or died
by 2 weeks, Si = 0 otherwise. Furthermore, let Xi be an indicator of low birth weight
(< 2.5 kg), i.e., Xi = 1 if the infant had low birth weight, 0 otherwise. Define Yi as
HIV infection status at 28 weeks where Yi = 1 if an infant is infected by 28 weeks. As
there is right censoring in the BAN study, a more formal analysis would correct for
censoring using a survival outcome but as this is for illustration we will assume Yi is
observed for all infants. The principal effect of interest is the difference in risk of HIV
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infection at 28 weeks between the infant ART and control arms for infants in the NI
stratum.
For estimation, the consistent moment-based estimators under Assumptions 1 and
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∑
(1 − Si)Zi and φˆx =
∑
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x)/
∑
(1−Si)(1−Zi). For pˆiz, the Aalen-J The estimates θˆu100, θˆl100, θˆu100x, and θˆl100x are










Table 3.2 presents data from this study by treatment and Xi. Using these data and
the above estimators, we have γˆ = (630/668)/(813/852) = 0.9884, pˆi1 = 0.0148, and
pˆi0 = 0.0507. Thus the estimated unadjusted upper and lower bounds are θˆ
u
100 = 0.0149,





Using the data stratified by Xi, γˆ0 = 1 and γˆ1 = 0.8612. Furthermore, pˆi10 = 0.0107,
pˆi11 = 0.0645, θˆ
u
1000 = 0.0107, θˆ
l
1000 = 0.0107, θˆ
u
1001 = 0.0749, θˆ
l
1001 = 0, λˆ0 = 0.9237,
λˆ1 = 0.0763, φˆ0 = 0.9270, and φˆ1 = 0.0730. Therefore, θˆ
u







X ] = [−0.0409,−0.0354]. Since Xi satisfies (3.9) empirically, i.e.,
pˆi10 > (1 − γˆ0) and pˆi11 < (1 − γˆ1), the estimated adjusted lower bound is larger than
the estimated unadjusted lower bound, consistent with Proposition 3. However, the
estimated adjusted upper bound is larger than the estimated unadjusted bound which
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seems to contradict Proposition 1.
In this example, γˆ = 0.9884 6= 0.9894 = ∑x γˆxλˆx even though γ = ∑x γxλx. This
suggests an alternative estimator for λx, namely λ˜x = λˆxαˆx where
αˆx =
∑







Note αˆx is a consistent estimator of Pr[Xi = x|Zi = 0]/Pr[Xi = x|Zi = 1], which equals
1 by Assumption 1, implying αˆx
p−→ 1 and thus λ˜x p−→ λx. Similarly, let φ˜x = φˆx/αˆx.










100xφ˜x will satisfy the
relationship given in Proposition 1, i.e., the adjusted bounds computed using φ˜x and
φ˜x will always be at least as narrow as the unadjusted bounds.
Using the BAN data, αˆ0 = 0.9912, αˆ1 = 1.0988, φ˜0 = 0.9346, φ˜1 = 0.0664.
Thus, θ˜u100X = 0.0149, and θ˜
l
100X = 0.0100, yielding adjusted bounds for CE of
[−0.0408,−0.0359]. That is, the adjusted bounds are 58% narrower than the unad-
justed bounds.
3.8 Identifiability
As noted at the end of Section 3.3, in the absence of covariate X, CE is identifiable
if and only if one of the following three conditions occur: γ = 1, pi1 = 1, or pi0 = 0.
When at least one of these conditions holds, CE is identifiable and θu100 = θ
l
100, i.e.,
the bounds collapse to a single point. In this section we consider conditions under
which adjusting for the binary covariate X renders CE identifiable in the sense that
the adjusted bounds collapse to a point, i.e., CElX = CE
u
X . By the form of the adjusted
bounds given in (3.7), it follows that if 0 < φ0 < 1, then the adjusted bounds yield a
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single point if and only if
γx = 1, pi1x = 1, or pi1x = 0 (3.10)




X if and only if




X if and only if (3.10)
holds for x = 0.
Ding et al. (2011) also considered identifiability of a principal effect when outcomes
are truncated by death, which is mathematically identical to the problem considered
here. In addition to Assumptions 1 and 2 above, Ding et al. provided two additional
assumptions which are sufficient for identifiability: (i) Xi ⊥ Yi|{Si(0), Si(1), Zi} and
(ii) Pr[Xi = x|Si(0) = Si(1) = 0] 6= Pr[Xi = x|Si(0) = 1, Si(1) = 0]. Unfor-
tunately, assumption (i), which under randomization can be equivalently stated as
Xi ⊥ Yi(z)|{Si(0), Si(1)} for z = 0, 1, cannot be verified from the observable data.
Ding et al. also gave sufficient identifiability conditions that do not require (i) but in-
stead require that X takes on at least three levels or is continuous and that the mean
of Y satisfies a particular linear model.
In contrast, condition (3.10) can be assessed from the observable data because γx,
pi1x and pi0x are all identifiable under Assumptions 1 and 2 only. Moreover, (3.10)
suggests a strategy for selecting X. In particular, if a covariate X can be found such
that (3.10) holds for x = 0, 1, then CE will be identifiable. If no such covariate is
available, then selecting X such that (3.10) approximately holds for x = 0, 1 should
yield adjusted bounds with width close to zero. For instance, in the MTCT from
the previous section, the low birth weight indicator covariate X yields γˆ0 = 1, i.e.,
(3.10) empirically holds for x = 0; while (3.10) does not hold empirically for x = 1,
pˆi11 = 0.065 is not too far from zero and indeed the birth weight adjusted bounds for
CE are substantially narrower than the unadjusted bounds.
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Finally, we note two special examples where Xi identifies CE. First, suppose Xi = 1
if and only if Si(0) = Si(1) = 0, i.e., Xi is a perfect predictor of membership in the NI
principal stratum. Because γ1 = 1, the causal effect is identifiable within the stratum




1001. Furthermore, because φ1 = 1 and φ0 = 0, it follows










X . This example is related
to the “principal score,” i.e., the probability an individual is within a principal stratum
conditional on one or more covariates (Jo and Stuart, 2009). In practice, principal
scores are not known but predicted based on fitted models using the observed data.
In the MTCT setting, such a model can be fit using data from infants with Zi = 0
and Si = 0, because under Assumptions 1 and 2 such infants are necessarily in the
NI stratum. This first example illustrates that if a set of one or more covariates (not
necessarily binary or even discrete) can be found such that the principal scores for the
NI stratum equal zero or one for all individuals and dichotomized at some threshold,
then CE is identified. In practice this may not be possible; however, if covariates
can be found such that the principal scores for the NI stratum are all close to zero or
one, i.e., the principal scores are highly predictive of NI stratum membership, then the
adjusted bounds constructed by stratifying on the dichotomized principal scores should
have width near zero. For the second example, suppose Yi = 1 if and only if Xi = 1,
i.e., Xi is a perfect predictor of Yi. Then pi10 = 0 and pi11 = 1 implying (3.10) holds
for x = 0 and x = 1 and therefore CElX = CE
u
X . In settings where Zi has an effect
on Yi and Zi is assigned randomly, no such perfect predictor Xi will exist (because




In summary, this paper considers when adjusted bounds of the principal effect will be
sharper than unadjusted bounds. In particular, Proposition 1 shows that the adjusted
bounds cannot be worse, i.e., wider, than the unadjusted bounds. Propositions 2 and 3
give necessary and sufficient conditions for the adjusted upper and lower bounds to be
an improvement. Throughout it was assumed that X was a binary covariate, although
the results from Section 3.6 can be extended to any categorical baseline covariate.
Specifically, Proposition 1 will hold for any categorical baseline covariate Xi with k
levels, k finite. Similarly, if there exists any two levels of X that satisfy either (3.8) or
(3.9), then either Proposition 2 or Proposition 3 will hold respectively.
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Figure 3.1: Graphical depiction of bounds discussed in Section 3.5 for the two fictional
trials from Section 3.5 stratified by two covariates. The solid lines depict equation (3.2)
with pi1 = 0.02 and γ = 0.95 in the upper panels and pi1 = 0.85 and γ = 0.8 in the
lower panels. The · · · (−−−) lines represent (3.5) for Xi = 0 (Xi = 1). The vertical
value of ◦ (+) corresponds to θu100X (θl100X).
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Table 3.1: Probabilities from the fictional trials described in Section 3.4 stratified by
X1 and X2
Trial 1 X1 X2
0 1 0 1
γx 0.995 0.920 0.980 0.880
pi1x 0.035 0.010 0.005 0.055
λx 0.400 0.600 0.700 0.300
φx 0.419 0.581 0.722 0.278
Trial 2 X1 X2
0 1 0 1
γx 0.890 0.740 0.875 0.625
pi1x 0.760 0.910 0.910 0.710
λx 0.400 0.600 0.700 0.300
φx 0.445 0.555 0.766 0.234
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Table 3.2: Data from the BAN study stratified by X (low birth weight < 2.5 kg).
Control Treatment
X X
0 1 Total 0 1 Total
S = 1 28 10 38 36 3 39
S = 0 584 46 630 751 62 813
Y = 1 31 1 32 8 4 12
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Chapter 4
Principal Surrogates in Repeated
Low-Dose Challenge Experiments
4.1 Introduction
Experiments in non-human primates (NHPs) play an essential role in the develop-
ment, screening, and evaluation of preventive HIV vaccines (Morgan et al. 2008; Fauci
et al. 2008). Historically, these studies have usually entailed challenges with very high
doses of a hybrid simian-human immunodeficiency virus (SHIV), resulting in infection
of all NHPs in the experiment. Such an approach uses doses that are much higher
than those experienced in natural transmission, so that the failure of a vaccine candi-
date to protect from infection in this setting is not necessarily indicative of a vaccine
without utility in humans (Feinberg and Moore 2002). Thus researchers have recently
begun to conduct repeated low-dose challenge (RLC) studies in NHPs (Garcia-Lerma
et al. 2008; Ellenberger et al. 2006; Subbarao et al. 2006; Otten et al. 2005) that may
more closely mimic typical exposure in natural human transmission settings. Recent
investigations (Regoes et al. 2005; Hudgens and Gilbert 2009; Hudgens et al. 2009)
have shown that these experiments can be adequately powered to detect vaccine effi-
cacy against infection with a clinically feasible numbers of NHPs. Since investigators
control exposure, challenge experiments can assess vaccine effects of interest that may
be difficult to observe in typical human efficacy trials. For example, since infection
can be assessed after each exposure via viral load assays, one can easily estimate the
per-exposure or “per-contact” effect of vaccination. Likewise, challenge studies allow
precise characterization of immunological and virological parameters very early after
infection, which are practically impossible to evaluate in humans (except possibly in
neonates).
In addition to assessing vaccine effects on infection and post-infection endpoints,
evaluation of immunological surrogates of protection (SoPs) are a vital component of
NHP challenge experiments, providing points of reference to judge new vaccine can-
didates and for retrospective analyses of candidates evaluated previously in high-dose
challenge experiments (Regoes et al. 2005). In general, a SoP is defined to be an im-
munological variable Si such that a vaccine effect on Si is predictive of a vaccine effect
on the risk of infection or disease. The utility of such a SoP includes guiding vaccine
development, providing guidance for regulatory and immunization policy decisions, and
bridging efficacy of a vaccine observed in a trial to a new setting. For RLC challenge
studies, knowledge of an immunological surrogate can inform comparisons of vaccine
candidates in NHPs and support predictions of vaccine efficacy in humans.
Despite the importance of finding immune SoP, the literature on methods for their
quantitative assessment is still quite limited. Moreover, there exists considerably con-
fusion about what constitutes an immune correlate or surrogate of protection and how
it is appropriately evaluated. Recently Qin et al. (2007) and Gilbert et al. (2008) pro-
posed a hierarchical three-tier framework for evaluating immune correlates: correlate
of risk (CoR), specific SoP, and general SoP. A CoR is an immunological measurement
that correlates with the rate or level of a clinical endpoint in a defined population. A
specific SoP is a CoR that is predictive of vaccine efficacy in a particular setting. A
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general SoP is a specific SoP that is also predictive of VES across different settings (e.g.,
across populations or across vaccine formulations). Meta-analysis of multiple vaccine
studies is required for evaluating a general SoP whereas one study may be sufficient
for evaluating a specific SoP. Here attention is restricted to the evaluation of a specific
SoP from a single RLC challenge study of a candidate HIV vaccine.
Traditionally, identification of potential specific SoPs has relied on solely assessing
whether a immune response was a CoR, i.e., associated with risk of infection or dis-
ease. For example, in the first phase III trial of an HIV vaccine, a significant negative
association was found between risk of HIV infection and antibody (Ab) response to the
vaccine (Gilbert et al. 2005). Unfortunately, this purely correlational analysis provides
no information to distinguish between two possibilities: (i) a greater vaccine effect on
the immune response predicted a greater vaccine effect on infection risk, or (ii) the
immune response simply marked an innate ability to escape infection but did not pre-
dict vaccine efficacy. In other words, it was not possible based on the observed data
to conclude whether Ab response to the vaccine was a SoP or just a CoR. A similar
example is given by Ellenberger et al. (2006), who found an association between vaccine
induced ELISpot Gag responses and risk of SHIV infection in a RLC challenge study
evaluating an HIV DNA/MVA vaccine candidate.
Recently, novel experimental designs and corresponding statistical methodology
have been proposed for evaluating potential specific SoPs in the context of human
efficacy trials (Follmann 2006; Gilbert and Hudgens 2008). The central premise behind
these designs is to attempt to elicit the immune response control NHPs would have
had if they had been vaccinated. The first design, which is referred to as the baseline
immunogenicity predictor or BIP design, entails measuring a baseline covariate(s) W
that is correlated with the immune response that NHP would have to the HIV vaccine
being evaluated. For example, W might be an immune response to a non-HIV vaccine.
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The missing HIV vaccine immune response for NHPs in the control arm can then be
predicted from their W and a prediction model based on observed data from the vaccine
group. In turn, the association between the vaccine induced immune response and the
vaccine effect to prevent infection can be assessed.
The second study design proposed for evaluation of SoPs in human efficacy trials is
the close-out placebo vaccination design, where placebo recipients who are uninfected
at the end of the trial are administered the HIV vaccine and their immune response is
measured. In the RLC challenge study setting, this design may not be feasible since
most, if not all, control NHPs are often infected after repeated challenges, e.g., see
Ellenberger et al. (2006) and Subbarao et al. (2006). Therefore this paper presents
a proposed modification of close-out placebo vaccination wherein after each challenge
uninfected control NHPs are randomly assigned to receive vaccine according to a pre-
specified crossover probability. This will be referred to as the crossover vaccination
(CrV) design.
Simulation studies of large (e.g., Phase III) randomized human efficacy trials have
demonstrated that the additional information provided by employing a BIP or close-
out placebo vaccination design can enable assessing the extent to which a CoR is a
SoP (Follmann 2006; Gilbert and Hudgens 2008). Similarly, Hudgens and Gilbert
(2009) demonstrated the BIP design also holds promise in identifying SoPs in the RLC
challenge study setting. However, the feasibility of the BIP design relies heavily on the
existence of a baseline covariate W that is correlated with the HIV vaccine immune
response. Whether such a covariate will be available may not be evident, especially
when evaluating new vaccine candidates. The CrV design, on the other hand, does not
require a BIP W . In order to further compare these two designs, methods are proposed
for assessing potential immunological SoPs using either the BIP or CrV design. The




To begin consider the usual two-arm RLC challenge study design where no NHPs
crossover from control to vaccine. For NHP i, let Zi be the treatment assignment
subject i was randomized to, where Zi = 0 is control and Zi = 1 is vaccine. Let
Ti(z) be the potential survival time under assignment z. It is assumed throughout that
survival time is measured by the number of exposures (i.e., challenges) until infection
with SHIV; thus Ti(z) is a positive integer. Let Si(Zi) denote the HIV-specific immune
response when assigned treatment Zi. Assume Si(0) = 0 for all i because vaccine anti-
gens (absent in the control) are necessary to induce an HIV-specific immune response.
Let p(Zi, Si(1)) denote the probability of infection from a single exposure (i.e., the
transmission probability) under assignment to treatment Zi.
The model and likelihoods developed below rely on several key assumptions. First,
assume no interference between NHPs and no variations in the type of vaccine such that
the stable unit treatment value assumption (SUTVA) holds. The lack of interference
between NHPs should hold in this setting since investigators can prevent transmission
of SHIV between NHPs. Second assume ignorable treatment assignment, i.e., Zi ⊥
(Si(1)), which is insured by the use of randomization in assigning NHPs to receive
vaccine or serve as a control. Third, assume the per-challenge probability of infection
is independent of the prior number of challenges.
Under these assumptions, following Follmann (2006), a model for the transmission
probability is
p(Zi, Si(1),Wi; β) = Φ{β1 + β2Zi + β3Si(1) + β4ZSi(1)}, (4.1)
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where Φ is the standard normal CDF and β ≡ (β1, β2, β3, β4). The linear component of
model (4.1) can easily be generalized to include baseline covariates. A key parameter
of model (4.1) is β4 since β4 6= 0 indicates that larger vaccine effects on the immune
response Si are associated with larger vaccine effects on the probability of infection.
The parameter β2 of model (4.1) is also important as it describes the vaccine effect on
infection not associated with the vaccine effect on Si. In a typical RLC challenge study
design, Si(1) is only observed when Zi = 1. Thus, intuitively, it is not expected for β to
be fully identifiable without additional information. The Appendix contains the proof
that β is indeed not identifiable when Si(1) follows a normal distribution. On the other
hand, β is identifiable when either the BIP or CrV designs are employed (Gilbert and
Hudgens 2008).
The average causal effect of the vaccine on survival is defined as h(E{Ti(0)|Si(1)},
E{Ti(1)|Si(1)}), where h is some contrast function such that h(x, y) = 0 iff x = y, e.g.,
h(x, y) = x− y, and E{Ti(Zi)|Si(1)} is the expected time to infection under treatment
Zi given immune response Si(1). Thus, Ti(Zi)|Si(Zi) is a geometric random variable
with E(Ti(z)|Si(z) = s) = 1/p(z, s). Following Hudgens and Gilbert (2009), choosing
h(x, y) = Φ−1(1/x)−Φ−1(1/y) yields convenient causal effects, i.e., h(E{Ti(0)|Si(1) =
s}, E{Ti(1)|Si(1) = t}) = −β2 − β3(t− s)− β4t.
The surrogate value of Si can be gleaned from the two curves p(0, s; β) and p(1, s; β).
Generally, larger |β4| and smaller |β2| will reflect greater surrogate value. Hudgens
and Gilbert (2009) suggest the proportion associative effect (PAE) statistic as a sum-
mary measure of the surrogate value of Si. PAE measures the proportion of the
total effect of treatment represented by the expected associative effect (EAE) of Si
versus the expected dissociative effect (EDE). EAE measures the association be-
tween the vaccine effect on Si and the vaccine effect on infection with larger values
of EAE implying stronger association. EDE measures the effect of vaccine in strata
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where Si(1) = Si(0) and is termed ‘dissociative’ since large values of EDE suggest
the opposite of an associative effect. Small values of EDE paired with large values
of EAE give strong indication that Si is an SoP. Thus, PAE = |EAE|/(|EAE| +
|EDE|). In general, EAE = E[h(E{Ti(0)|Si(1)}, E{Ti(1)|Si(1)})|Si(1) > Si(0)] and
EDE = E[h(E{Ti(0)|Si(1)}, E{Ti(1)|Si(1)})|Si(1) = Si(0)]. Using the h described
above EAE = −β2 − κβ4, where κ = E[Si(1)|Si(1) > Si(0) = 0], EDE = −β2 and
PAE ≡ |β2 + κβ4|/{|β2|+ |β2 + κβ4|}, (4.2)
where the convention |0|/(|0| + |0|) = 0.5 is used if β2 = β4 = 0. Note if β4 = 0, then
PAE = 0.5, corresponding to no association between the vaccine effect on Si and the
vaccine effect on infection. On the other hand, if β2 = 0 and β4 6= 0, then PAE = 1,
indicating there is a vaccine effect on infection if and only if there is a vaccine effect
on Si. Biomarkers with some surrogate value will have PAE ∈ (0.5, 1], with the value
increasing as PAE nears 1.
4.2.1 Baseline Immunogenicity Predictor Design
The likelihood for the BIP design can be constructed as follows. For NHP i, let Ti ≡
min{Ti(0)(1−Zi) +Ti(1)Zi, cmax} denote the observed number of exposures during the
experiment where cmax denotes the right censoring time, i.e., the maximum allowable
number of exposures. In general cmax may differ from NHP to NHP, but here for
simplicity it is assumed cmax is the same for all NHPs. LetWi denote a baseline covariate
that might be correlated with Si(1). Let δi equal 1 (0) if subject i is infected (uninfected)
by the end of the study and let Si ≡ Si(0)(1−Zi)+Si(1)Zi denote the observed immune
response. Suppose n iid copies of (Zi, Ti, δi, Si,Wi) are observed. Letting Gw denote
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ϕ(1, Si, Ti, δi; β)
Zi
{∫
ϕ(0, s, Ti, δi; β)dGw(s|Wi)
}1−Zi
,
where ϕ(Z, S, T, δ; β) ≡ {1− p(Z, S; β)}T−δp(Z, S; β)δ.
4.2.2 Crossover Vaccination Design
Next consider the likelihood for the CrV design. Recall in this design that after each
challenge uninfected control NHPs are randomly assigned to receive vaccine according
to a pre-specified crossover probability (cp). Let T
0
i denote the observed number of
challenges when the NHP was unvaccinated and δ0i be an indicator which equals one




i similarly for when the NHP
was vaccinated. For NHPs randomly assigned to receive vaccine at the start of the
experiment let T 0i = δ
0
i = 0. For NHPs randomly assigned to control at the start
of the experiment who become infected prior to crossover or reach the end of the
experiment prior to crossover let T 1i = δ
1
i = 0. Let Z˜i indicate vaccination at some











i > 0]) are observed. Letting G be the marginal distribution





















If the CrV and BIP designs are combined such that Wi is also observed for i =
1, . . . , n, then the conditional likelihood is the same as Lcrv except that dG(s) is replaced
by dGw(s|Wi) in (4.3).
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4.2.3 Inference
When Si(1) is normal β is unidentifiable even though G (Gw) can be identified.
Therefore, maximum “estimated likelihood” (Pepe and Fleming 1991) or “pseudolikeli-
hood” (Liang and Self 1996) can be used for inference. Maximum estimated likelihood
estimation (MELE) entails two steps. First obtain an estimate Gˆ (or Gˆw) using data
from the vaccine arm of the study. Then, conditional on Gˆ (or Gˆw), the MELE βˆ is
obtained by maximizing the likelihood Lbip (or Lcrv) with respect to β. The estimator







metric bootstrap test (PBT) (Davidson and Hinkley 1997; Hudgens and Gilbert 2009)
can be employed to assess H0 : PAE = 0.5 versus HA : PAE > 0.5, i.e., test the null
Si has no surrogate value versus the alternative Si has some surrogate value. The null
value of PAE = 0.5 is found by fixing β4 = 0 or β4 = −2κβ2.
4.3 Simulation study
A simulation study was conducted to assess whether sample sizes typical of RLC
challenge studies provide adequate power to detect immune responses with high surro-
gate value. Data were generated assuming 10, 15, 20, and 25 NHPs were randomized
to each arm initially, a maximum number of exposures per NHP of cmax = 10, and
model (4.1). Several RLC challenges studies with roughly 25 NHPs per arm are cur-
rently being conducted or planned by the NIH Vaccine Research Center (John Mascola,
personal communication).
Simulation studies were conducted where values of (Si(1),Wi) were generated using
the method of Emrich and Piedmonte (1991), which first generates a bivariate normal
random variable and truncates it to a create a bivariate binary random variable with
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(Si(1),Wi) each having success probability 1/2 and correlation ρ. Values of β were se-
lected such that the average probability of infection per challenge for controls (vaccines)
was 0.5 (0.1). Thus the vaccine efficacy (V E), i.e., percent reduction in the average
probability of infection due to vaccination, was (1-0.1/0.5) x 100 = 80%. To reflect
immune responses with varying surrogate values, simulated data sets were generated
under five scenarios corresponding to PAE ∈ {0.5, 0.6, 0.7, 0.8, 0.9}. For the first sce-
nario β = (−1,−1.85, 2,−1.12) such that PAE = 0.7. Values for β for the remaining
scenarios were chosen such that the desired PAE was achieved with p(1, Si(1); β) the
same as in the first scenario. Different values of the crossover probability cp were also
investigated to ascertain the optimal cp to detect a SoP. For each scenario, 1000 simu-
lated data sets were generated. For each data set maximum likelihood estimates βˆ and
P̂AE were computed and a PBT using 100 boots was performed for H0 : PAE = 0.5
versus H0 : PAE > 0.5 at the α = 0.10 significance level.
Simulation results for the case where (Si(1),Wi) are binary are given in Figure 4.1
and Tables 4.1 and 4.2. In general, there is power to reject H0 : PAE = 0.5 if neither
the BIP or CrV designs, which is surprising. However, as shown in the Appendix, β is
identifiable, up to absolute value, when Si(1) is binary. There is an increase in power
when using the CrV alone, but it appears that using a small cp, < 0.2, may be preferred
as there was an overall decrease in power for cp ≥ 0.2 versus cp ≤ 0.2.
One potential drawback of the CrV design is that there are fewer challenges of
unvaccinated NHPs, potentially diminishing the power to detect V E. Therefore we
also conducted simulation studies to assess how cp affects the power to reject the
null H0 : V E = 0. Simulations were performed for V E ∈ {0, 0.25, 0.50, 0.75} and
cp ∈ {0, 0.1, 0.2, 0.3, 0.4, 0.5}. The null H0 : V E = 0 is equivalent to testing H0 :
p(1)− p(0) = 0, where p(z) is the probability of infection under treatment z, and was
conducted using a likelihood ratio test. Results shown in Table 4.3 demonstrate the
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CrV design results in modest diminution of power to detect a vaccine effect on infection.
4.4 Discussion
A drawback in determining if a biomarker is a SoP in a RLC study is estimation of
Si(1) in the unvaccinated subjects. Previously, Follmann (2006) developed methods for
a BIP to be used to more accurately determine an SoP and also outlined the close-out
placebo vaccination (CPV). We have presented an innovative adaptation of his design,
the CrV, that provides a number of improvements. If all control subjects are infected
under the CPV design, there will be no subjects to receive vaccination at the end of the
trial. This scenario is not as likely in a RLC study. Employing the CrV will increase the
probability of measuring Si(1) for some control subjects, given the infection probability
at the first challenge is not one. Also, Follmann found that without incorporating a
BIP, the CPV design had little power to detect an SoP, whereas we have shown the
CrV, while more powerful when a BIP is present, has decent power to detect an SoP.
Additionally, the CrV design has little effect on power to detect V E.
Huang and Gilbert (2011) suggest alternative measures to the PAE for assessing
SoPs when multiple biomarkers are present. Specifically, the suggest using the stan-
dardized total gain (STG), a graphical measure which estimates the amount of vari-
ability of the treatment effect that is characterized by the risk difference between treat-
ment arms. Where PAE measures how well Si(0) − Si(1) predicts treatment effects,
STG measures the amount of variability in Pr[Yi(0) = 1] − Pr[Yi(1) = 1] explained
by Pr[Yi(0) = 1|Si(0), Si(1)] − Pr[Yi(1) = 1|Si(0), Si(1)], where Yi is the outcome of
interest and Si can be a vector of potential surrogates. Future research could entail
investigating the applicability of STG in the RLC setting by adapting (4.3) to estimate
STG under the CrV design, potentially gaining the flexibility to estimate the surrogate
value of multiple biomarkers in a RLC study.
71
Figure 4.1: Empirical type I error and power to reject H0 : PAE = 0.5 versus HA :
PAE > 0.5 from simulation study described in Section 4.3 with 25 NHPs in each arm
and (Si(1),Wi) binary.

















































































Table 4.1: Results from simulation study described in Section 4.3 with (Si(1),Wi)
binary. Each table entry is based on 500 simulated data sets with m NHPs per arm for
cp = 0, 0.1. ρ is the linear correlation. Bias is the median bias and EP is the empirical
power for the PBT of H0 : PAE = 0.5 versus HA : PAE > 0.5 at level α = 0.1.
m = 10 m = 15 m = 20 m = 25
cp PAE ρ Bias EP Bias EP Bias EP Bias EP
0 0.5 0 0.267 0.067 0.240 0.093 0.242 0.087 0.227 0.092
0.5 0.259 0.062 0.251 0.084 0.231 0.087 0.230 0.074
0.9 0.234 0.044 0.238 0.063 0.235 0.083 0.233 0.077
0.7 0 0.2 0.235 0.055 0.361 0.027 0.462 0.001 0.583
0.5 0.139 0.247 0.044 0.371 0.020 0.49 -0.001 0.626
0.9 0.034 0.340 0.032 0.416 0.023 0.546 0.018 0.649
0.9 0 0.362 0.208 0.221 0.365 0.128 0.522 0.103 0.597
0.5 0.063 0.360 0.034 0.620 0.015 0.772 0.007 0.875
0.9 -0.011 0.59 -0.014 0.835 -0.005 0.952 0.003 0.977
0.1 0.5 0 0.219 0.087 0.216 0.092 0.216 0.101 0.211 0.080
0.5 0.224 0.080 0.220 0.083 0.220 0.081 0.217 0.085
0.9 0.220 0.064 0.232 0.077 0.235 0.068 0.227 0.077
0.7 0 0.038 0.314 0.009 0.415 -0.005 0.487 0.002 0.549
0.5 0.042 0.307 0.016 0.393 0.018 0.483 0.006 0.618
0.9 0.018 0.314 0.011 0.424 0.012 0.575 0.010 0.673
0.9 0 0.043 0.439 0.022 0.707 0.009 0.844 0.003 0.925
0.5 0.025 0.470 0.013 0.771 0.005 0.910 0.010 0.956
0.9 -0.013 0.616 -0.011 0.857 -0.012 0.956 -0.003 0.993
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Table 4.2: Results from simulation study described in Section 4.3 with (Si(1),Wi)
binary. Each table entry is based on 500 simulated data sets with m NHPs per arm for
cp = 0.2, 0.4. ρ is the linear correlation. Bias is the median bias and EP is the empirical
power for the PBT of H0 : PAE = 0.5 versus HA : PAE > 0.5 at level α = 0.1.
m = 10 m = 15 m = 20 m = 25
cp PAE ρ Bias EP Bias EP Bias EP Bias EP
0.2 0.5 0 0.187 0.107 0.208 0.104 0.205 0.088 0.208 0.083
0.5 0.227 0.068 0.219 0.103 0.215 0.098 0.215 0.079
0.9 0.211 0.064 0.228 0.065 0.226 0.065 0.229 0.070
0.7 0 0.034 0.311 0.000 0.394 0.002 0.463 0.012 0.49
0.5 0.032 0.312 0.004 0.386 0.009 0.468 0.003 0.537
0.9 -0.015 0.292 -0.012 0.416 0.004 0.547 0.008 0.65
0.9 0 0.022 0.483 0.023 0.715 0.015 0.856 0.017 0.922
0.5 0 0.526 0.008 0.784 0.019 0.909 0.014 0.964
0.9 -0.033 0.609 -0.019 0.871 -0.007 0.958 -0.001 0.990
0.4 0.5 0 0.162 0.089 0.194 0.092 0.208 0.097 0.220 0.083
0.5 0.158 0.071 0.212 0.097 0.207 0.091 0.216 0.065
0.9 0 0.06 0.216 0.086 0.217 0.072 0.215 0.063
0.7 0 0.007 0.252 -0.005 0.386 0.033 0.369 0.023 0.429
0.5 -0.009 0.259 0.014 0.346 0.027 0.381 0.034 0.449
0.9 -0.060 0.276 -0.032 0.394 0.000 0.486 -0.005 0.656
0.9 0 0.027 0.445 0.044 0.658 0.038 0.832 0.046 0.918
0.5 0.009 0.482 0.024 0.719 0.036 0.879 0.040 0.952
0.9 -0.041 0.581 -0.014 0.825 -0.014 0.941 0.001 0.987
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Table 4.3: Empirical power to reject H0 : V E = 0 where V E ≡ {1 − p(1)/p(0)} ×
100% is the percent reduction in the per-challenge risk of infection due to vaccination.
Simulation results assuming 50 NHPs total, with 25 randomized to vaccine initially.
The average number of control NHPs that crossover are given in parentheses. The
parenthetical numbers in the column headers denote the theoretical expected value of
the number of NHPs that crossover.
Crossover probability (cp)
VE 0 (0) 0.1 (2.3) 0.2 (4.2) 0.3 (5.8) 0.4 (7.1) 0.5 (8.3)
0 0.04 (0) 0.06 (2.3) 0.06 (4.1) 0.06 (5.8) 0.06 (7.2) 0.05 (8.4)
0.25 0.26 (0) 0.25 (2.3) 0.24 (4.2) 0.26 (5.8) 0.23 (7.2) 0.22 (8.4)
0.5 0.89 (0) 0.87 (2.3) 0.83 (4.2) 0.82 (5.8) 0.8 (7.2) 0.77 (8.3)




To summarize, assessing the causal effect of interventions to prevent infectious dis-
eases can be difficult in many settings. We have provided methodology to assess the
principal effect of treatment on competing risks outcomes. This work can be considered
an extension of Shepherd et al. (2007), who measured the principal effect on a survival
endpoint. Nonparametric bounds and sensitivity methods were created to determine
how the potential selection bias affects the estimate of the principal effect. These meth-
ods were evaluated by simulation studies and found to be precise and accurate. We
then analyzed the BAN study, a recent large study of mother-to-child transmission of
HIV.
Because unadjusted bounds of principal effects are frequently uninformative, we
have demonstrated methods to calculate adjusted bounds. These bounds, as outlined
by Grilli and Mealli (2008), incorporate information from a binary baseline covariate
X to create adjusted bounds. Unadjusted bounds are found within strata of X and
are averaged to create the overall adjusted bounds. We have shown that the adjusted
bounds can improve on the unadjusted bounds, i.e, be narrower than, and have pro-
vided the necessary and sufficient conditions when this will occur. Relaxation of the
monotonicity assumption and methods for adjusting for multiple covariates are two
possible directions for future research.
Additionally, surrogate evaluation requires consideration of novel study designs. Ac-
cordingly, we developed a new design for evaluation of surrogates of vaccine protection
in RLC challenge experiments, the crossover vaccination (CrV) design. This new de-
sign was an adaptation of the close-out placebo vaccination of Follmann (2006) and
also incorporated the use of a baseline covariate to improve estimation. The CrV was
investigated under different scenarios using simulation studies and found to be adequate
in the estimation and testing of potential surrogates, measured using the proportion
associative effect (PAE) and vaccine efficacy (V E). It is believed that the CrV can be
used to estimate of other measures of surrogacy, such as the standardized total gain
developed by Huang and Gilbert (2011).
Causal inference, more specifically principal stratification, is the thread that binds
this dissertation together. Chapters 2 and 3 provide methods for analysis within a prin-
cipal stratum of interest while the approach addressed in Chapter 4 compares quantities
across all strata, i.e., compares effects in the stratum where Si(0) = Si(1) to the effects
in the strata where Si(0) 6= Si(1). For example, for the BAN study addressed in Section
2.5, the causal effect that was estimated is for infants that would never infected under
either treatment assignment, (Si(0) = Si(1) = 0) whereas the measure of a biomarker’s
potential as a surrogate of protection is averaged across all possible values of Si(1)
conditional on Si(0) = 0.
In general, principal stratification should be viewed as a tool for researchers to use
in settings where traditional methods do not yield causal interpretations. As pointed
out by Pearl (2011), one should be careful when using principal stratification to define
research questions but instead let it be an aid to answer causal questions when other
methods fail. However, in some settings when a proper or well defined question may
be lacking, principal stratification can be used to guide future research, i.e, the search
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for surrogates of protection, specifically see Gilbert, Hudgens, and Wolfson (2011).
Thus, I believe further research in principal stratification methods will allow investiga-
tors, specifically those of public health issues, to conduct studies and trials that more
efficiently and accurately determine a treatment’s casual effect on an outcome.
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Appendix I
Asymptotic Results for Chapter 2
Asymptotic Variances of FˆNI,up1 (t, j) and Fˆ
NI,low
1 (t, j)
To derive the asymptotic variances of FˆNI,up1 (t, j) and Fˆ
NI,low
1 (t, j), we first derive
the large sample variance of γˆ. Under monotonicity, it is straightforward to show
γˆ − (N0/n0)/ (N1/n1) p−→ 0, implying γˆ and (N0/n0)/(N1/n1) have the same limiting
distribution; therefore for the derivation below we can assume γˆ = (N0/n0)/(N1/n1).
For z, s = 0, 1, define pzs =
∑
I[Zi = z, Si = s]/n and pizs = Pr[Zi = z, Si = s],
and let p = (p00, p01, p10, p11)
′ and pi = (pi00, pi01, pi10, pi11)′. Define the function g as
g(pi) = pi00(pi10 + pi11)/{pi10(pi00 + pi01)} and note that g(p) = γˆ and g(pi) = γ. Then by
the multivariate central limit theorem and the delta method (e.g., see Agresti 2002 ,
page 580),
√





z,s=0 pizs∇gzs)2 and ∇gzs = ∂g(pi)/∂pizs. It follows from straightforward algebra that
σ2γ = γ
2[pi01/{pi00(pi00 + pi01)} + pi11/{pi10(pi10 + pi11)}] for which a consistent estimator
is σˆ2γ = γˆ
2n(1/N0 − 1/n0 + 1/N1 − 1/n1).
For fixed t and j, let θtj = (F1(t, j), γ)
′ and θˆtj = (Fˆ1(t, j), γˆ)′. Under the condi-
tions stated in Section 2.3.1 of the main text, in particular assuming equation (2.6),
it is straightforward to show FˆNI,up1 (t, j) − Fˆ1(t, j)/γˆ p−→ 0, implying FˆNI,up1 (t, j) and
Fˆ1(t, j)/γˆ have the same limiting distribution. Therefore we can assume Fˆ
NI,up
1 (t, j) =
Fˆ1(t, j)/γˆ and, analogously, by equation (2.8) of the main text we can assume
FˆNI,low1 (t, j) = {Fˆ1(t, j)−(1−γˆ)}/γˆ. Define the vector of functions h(x, y) = (x/y, {x−
(1− y)}/y)′ such that h(θˆtj) = (FˆNI,up1 (t, j), FˆNI,low1 (t, j))′. Because Fˆ1(t, j) and γˆ are
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consistent and asymptotically normal, by the delta method
√









and σ2tj is the asymptotic variance of
√
n{Fˆ1(t, j)−F1(t, j)} such that in large samples
var{Fˆ1(t, j)} = σ2tj/n. It follows that FˆNI,up1 (t, j) and FˆNI,low1 (t, j) are asymptotically
normal with variances
















Replacing var{Fˆ1(t, j)}, γ, F1(t, j), and σ2γ in (A.1) and (A.2) with v̂ar{Fˆ1(t, j)}, γˆ,
Fˆ1(t, j), and σˆ
2
γ yields equations (2.7) and (2.9) from the main text.
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Appendix II
Proofs from Chapter 3































where the inequality holds since min{a1, b1}+ min{a2, b2} ≤ min{a1 + a2, b1 + b2} and








Pr[Yi(1) = 1|Si(1) = 0, Xi = x]




Pr[Yi(1) = 1, Si(1) = 0, Xi = x] Pr[Si(1) = 0, Xi = x] Pr[Xi = x, Si(0) = Si(1) = 0]




Pr[Yi(1) = 1, Si(1) = 0, Xi = x]




Pr[Yi(1) = 1, Xi = x|Si(1) = 0]

































where the inequality holds because max{a1, 0}+ max{a2, 0} ≥ max{a1 +a2, 0} and the
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Pr[Si(0) = 1|Si(1) = 0, Xi = x]




Pr[Si(0) = 1, Si(1) = 0, Xi = x]
Pr[Si(1) = 0, Xi = x]
Pr[Si(1) = 0, Xi = x] Pr[Xi = x, Si(0) = Si(1) = 0]




Pr[Si(0) = 1, Si(1) = 0, Xi = x]




Pr[Si(0) = 1, Xi = x|Si(1) = 0]





Proof of Proposition 2
First, suppose (3.8) holds and, without loss of generality, assume pi10 < γ0 and pi11 > γ1
which implies that θu1000 = pi10/γ0 and θ
u
1001 = 1. If θ
u

















where the inequality holds because pi11/γ1 > 1. Likewise, if θ
u







φ0 + φ1 < φ0 + φ1 = 1 = θ
u
100,




Now suppose that (3.8) is not satisfied. Suppose that pi1 < γ, which implies that
θu100 = pi1/γ. Furthermore suppose pi1x > γx for x = 0, 1. Thus, λ0pi10 > λ0γ0 and
λ1pi11 > λ1γ1 implying that
λ0pi10 + λ1pi11 > λ0γ0 + λ1γ1
pi1 > γ,
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which is a contradiction. Thus, pi1x < γx for x = 0, 1 and θ
u




θu100xφx = pi10/γ0φ0 + pi11/γ1φ1 = pi1/γ = θ
u
100.
A analogous argument exists when pi1 > γ and combined with the result above we







only if X satisfies (3.8). 
Proof of Proposition 3
Without loss of generality, assume pi10 > (1− γ0) and pi11 < (1− γ1) which implies that





pi10 − (1− γ0)
γ0
φ0 >
pi10 − (1− γ0)
γ0
φ0 +




pi1 − (1− γ)
γ
= θl100,





pi10 − (1− γ0)
γ0
φ0 > 0 = θ
l
100.
where the inequality holds since {pi10 − (1− γ0)}/γ0 > 0. Thus, if (3.9) is satisfied by
X then θl100X > θ
l
100.
Suppose that pi1 > 1− γ, which implies that θl100 = {pi1− (1− γ)}/γ. Now suppose
that (3.9) is not satisfied and furthermore suppose pi1x < 1−γx for x = 0, 1. For λx > 0,
λ0pi10 < λ0(1− γ0) and λ1pi11 < λ1(1− γ1) implying that
λ0pi10 + λ1pi11 < λ0(1− γ0) + λ1(1− γ1)
pi1 < 1− γ,
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pi10 − (1− γ0)
γ0
φ0 +
pi11 − (1− γ1)
γ1
φ1 = {pi1 − (1− γ)}/γ = θl100.
A analogous argument exists when pi1 < 1 − γ and combined with the previous result







only if X satisfies (3.9). 
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Appendix III
Identifiability Results from Chapter 4
Here we show β = (β1, β2, β3, β4) is not identifiable in the usual RLC challenge study
design (i.e., without CrV or BIP) assuming Si(1) is binary. Since treatment assignment
is random and S(1) is observed in all NHPs randomized to Zi = 1, G(s) is identifiable
and can be regarded as fixed and known. Assume the βs are all finite, so that there is a
positive probability of (not) observing an infection under either treatment assignment.
Also for now assume G(s) is discrete and the mass is not concentrated on a single point.
Under these assumptions, β1 + β2 and β3 + β4 are identifiable. To see this, suppose
there are two parameterizations β = (β1, β2, β3, β4) and β˜ = (β˜1, β˜2, β˜3, β˜4) such that
Pr[Ti = t, δi = d, Si = s|Zi = 1; β] = Pr[Ti = t, δi = d, Si = s|Zi = 1; β˜] (5.4)
for all t, d, s. Then, for some s1 6= s2, t = 1, d = 1, (5.4) implies
Φ{β1 + β2 + (β3 + β4)s1} = Φ{β˜1 + β˜2 + (β˜3 + β˜4)s1}
and
Φ{β1 + β2 + (β3 + β4)s2} = Φ{β˜1 + β˜2 + (β˜3 + β˜4)s2}.
Since Φ is invertible, this implies
β1+β2+(β3+β4)s1 = β˜1+β˜2+(β˜3+β˜4)s1 and β1+β2+(β3+β4)s2 = β˜1+β˜2+(β˜3+β˜4)s2,
implying β1+β2 = β˜1+β˜2 and β3+β4 = β˜3+β˜4, thus β1+β2 and β3+β4 are identifiable
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The more interesting issue is whether β2 and β4 individually are identifiable from
the observable data. To show this we will show that β1 and β3 are identifiable. Similar
to the argument above, suppose there are two parameterizations β = (β1, β2, β3, β4)
and β˜ = (β˜1, β˜2, β˜3, β˜4) such that
Pr[Ti = t, δi = d, Si = s|Zi = 0; β] = Pr[Ti = t, δi = d, Si = s|Zi = 0; β˜] (5.5)
Then for t = 1, d = 1, (5.5) implies
∫
Φ(β1 + β3s)dG(s) =
∫
Φ(β˜1 + β˜3s)dG(s) (5.6)
Now if we were considering a single dose challenge study (i.e., cmax = 1), then the only
other possible pattern of observed data under Zi = 0 would be t = 1, d = 0, in which
case (5.5) implies
∫
{1− Φ(β1 + β3s)}dG(s) =
∫
{1− Φ(β˜1 + β˜3s)}dG(s) (5.7)
Now suppose, without loss of generality that β˜3 6= 0. Then if we let and β3 = 0 and
β1 = Φ
−1{∫ Φ(β˜1 + β˜3s)dG(s)} then (5.6) and (5.7) hold, yet β3 6= β˜3. That is, β1 and
β3 are not identifiable in a single dose challenge study. Fortunately, in repeated low
dose studies (cmax > 1) we are not limited to the two observed data patterns above. In
particular, for t = 2, d = 1, (5.5) implies
∫
{1− Φ(β1 + β3s)}Φ(β1 + β3s)dG(s) =
∫
{1− Φ(β˜1 + β˜3s)}Φ(β˜1 + β˜3s)dG(s) (5.8)








Now the question becomes whether (5.6) and (5.9) together imply β1 = β˜1 and β3 = β˜3.
This seems plausible since we have two equations and two unknowns. Below we provide
proof that β1 and β3 are identifiable if Si(1) is binary.
Assume Si(1) is binary with Pr[Si(1) = 1] = θ, Pr[Si(1) = 0] = 1 − θ, 0 < θ < 1.
Below we prove if θ 6= 1/2 , then β1 and β3 are identifiable. If θ = 1/2, only |β3| is
identifiable. To begin, note (5.5) is equivalent to
(1− θ)At−d(1− A)d + θBt−dBd = (1− θ)Ct−d(1− C)d + θDt−dDd
for all t, d where A = 1−Φ(β1), B = 1−Φ(β1+β3), C = 1−Φ(β˜1), D = 1−Φ(β˜1+ β˜3).
Showing A = C and B = D is equivalent to proving β1 and β3 are identifiable. Since
Φ is one-to-one function and 1 − Φ(β1) = A = C = 1 − Φ(β˜1) implies β1 = β˜1 (and
similarly β3 = β˜3). For d = 0, we have
(1− θ)At + θBt = (1− θ)Ct + θDt for t = 1, 2, . . . (5.10)
Now for t = 1 we have
(1− θ)(A− C) = θ(D −B) (5.11)
If A = C, then B = D and identifiability is proved. So assume by way of contradiction
A 6= C, and thus D 6= B. Now for t = 2, 3 we have
(1− θ)(A2 − C2) = θ(D2 −B2) (5.12)
(1− θ)(A3 − C3) = θ(D3 −B3) (5.13)
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Dividing (5.13) and (5.13) by (5.11) yields
A+ C = D +B) (5.14)
A2 + AC + C2 = D2 +DB +B2 (5.15)
Squaring (5.15) and subtracting it by (5.15) yields
AC = BD (5.16)
Squaring (5.15) and then subtracting it by four times of (5.16) on both sides gives
(A− C)2 = (B −D)2 (5.17)
Assume without loss of generality that A > C. Then (5.11) implies D > B which by
(5.17) in turn implies
A− C = B −D. (5.18)
Note (5.11) implies
A− C = θ
1− θ (D −B). (5.19)
Together (5.18) and (5.19) imply
0 =
1− 2θ
1− θ (D −B).
If θ 6= 1/2, this implies D = B, a contradiction. Thus if θ 6= 1/2, then β1 and β3 are
identifiable, and likewise β2 and β4.
Now suppose θ = 1/2. Equation (5.5) is equivalent to
At +Bt = Ct +Dt for t = 1, 2, . . . (5.20)
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There are at least two sets of solution to (5.20). One is A = C and B = D, which
implies β1 = β˜1 and β3 = β˜3. Another solution is A = D and B = C, or consequently
β1 = β˜1 + β˜3 and β1 + β3 = β˜3, which implies β3 = −β˜3. Thus if θ = 1/2, only |β3| is
identifiable implying that β4 is not identifiable because if β3 > 0 then β4+β3−|β3| = β4
but if β3 < 0 then β4 + β3 − |β3| = β4 + 2β3.
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